小児内分泌疾患の治療

出版社： 診断と治療社
著者：
発行日： 2022-08-10
分野： 臨床医学：内科  >  小児科学一般
ISBN： 9784787825469
電子書籍版： 2022-08-10 （電子版）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：4～8営業日

7,920 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

7,920 円(税込)

購入する

商品紹介

1997年に初版が発行され，2002年，2007年，2017年と改訂版が発行されてきた「小児内分泌疾患の治療」を，日本小児内分泌学会が責任編集として改訂．最良の治療法だけではなく，小児の治療で問題となる未承認薬・適応外薬の使用や救急対応もまとめられ，現場での適切な対応を可能としている．教科書である「小児内分泌学」とともに，小児科医師のみならず，成人内分泌科医など多くの医師に読んでいただきたい1冊．

目次

  • 第1章 成長障害
    A 低身長
     1 成長ホルモン分泌不全性低身長症
     2 Turner症候群における成長障害
     3 軟骨無形成症・低形成症
     4 Noonan症候群における成長障害
     5 Prader-Willi症候群における成長障害
     6 SGA性低身長症
     7 小児慢性腎不全性低身長症
     8 成長ホルモン不応症
      1．成長ホルモン不応症
      2．IGF-Ⅰ欠損症，IGF-Ⅰ受容体異常症
     9 その他の低身長
     10 低身長思春期発来
    B 高身長

    第2章 視床下部・下垂体障害による内分泌疾患
    A 下垂体機能低下症（下垂体近傍疾患を含む）
     1 新生児に起きうる汎下垂体機能低下症
     2 間脳－下垂体近傍腫瘍
     3 リンパ球性漏斗下垂体炎
     4 視床下部－下垂体近傍の炎症・感染症
    B 下垂体機能亢進症
     1 高プロラクチン血症
     2 下垂体性巨人症

    第3章 水・電解質代謝障害
    A 中枢性尿崩症
    B 中枢性尿崩症の周産期の管理
    C 口渇中枢障害を伴う高ナトリウム血症（本態性高ナトリウム血症）
    D 腎性尿崩症
    E 乳幼児習慣性多飲多尿
    F 低浸透圧症候群
     1 抗利尿ホルモン不適切分泌症候群
     2 中枢性塩喪失症候群（CSWS）
    G 夜尿症

    第4章 思春期発来異常をきたす疾患
    A 思春期早発症
     1 ゴナドトロピン依存性思春期早発症
     2 ゴナドトロピン非依存性思春期早発症
      1．hCG産生腫瘍
      2．家族性男性思春期早発症
      3．McCune-Albright症候群
      4．自律性反復性卵巣嚢胞
     3 内分泌疾患に伴う続発性思春期早発症
      1．先天性副腎過形成症に伴うゴナドトロピン非依存性思春期早発症
      2．Cushing症候群に伴うゴナドトロピン非依存性思春期早発症
      3．甲状腺機能低下症に伴うゴナドトロピン非依存性思春期早発症
      4．脳腫瘍の放射線治療後に起こるゴナドトロピン依存性思春期早発症
     4 部分型思春期早発症
      1．早発乳房
      2．早発陰毛・早発腋毛
      3．早発月経
    B 体質性思春期遅発症
    C 性腺機能低下症
     1 低ゴナドトロピン性性腺機能低下症
     2 高ゴナドトロピン性性腺機能低下症

    第5章 性分化・性発達異常を伴う疾患
    A 性分化へのアプローチ
     1 法律上の性の決定
     2 男性ホルモンによる治療
     3 女性ホルモンによる治療
     4 男性外陰部形成術
     5 女性外陰部形成術
    B Turner症候群
    C Klinefelter症候群
    D 月経の異常を伴う疾患
     1 続発性無月経，機能性無月経
     2 多嚢胞性卵巣症候群
     3 若年性機能性子宮出血
    E トランスジェンダーと性別違和

    第6章 副腎疾患
    A 副腎機能低下症
     1 先天性副腎低形成症
     2 後天性原発性副腎機能低下症
     3 二次性副腎機能低下症（ACTH分泌不全）とACTH不応症
      1．二次性副腎機能低下症（ACTH分泌不全）
      2．ACTH不応症
     4 副腎白質ジストロフィー
     5 アルドステロン合成酵素欠損症
    B 急性副腎不全
    C 副腎不全の予防
     1 合成ステロイドによる慢性副腎不全
     2 慢性副腎不全患者の手術等
     3 急性期離脱後循環不全（早産児晩期循環不全）
    D 先天性副腎過形成症
     1 21水酸化酵素欠損症
     2 先天性リポイド副腎過形成症（STAR異常症）
     3 17α水酸化酵素欠損症
     4 11β水酸化酵素欠損症
     5 3β水酸化ステロイド脱水素酵素欠損症
     6 P450酸化還元酵素欠損症
     7 先天性副腎過形成症の生殖能力と妊娠の管理
      1．21水酸化酵素欠損症
      2．先天性リポイド副腎過形成症
     8 21水酸化酵素欠損症の胎児治療
    E Cushing症候群（Cushing病を含む）
    F 高血圧を特徴とする疾患
     1 グルココルチコイド奏効性アルドステロン症
     2 見かけの鉱質コルチコイド過剰症候群（AME）
    G 褐色細胞腫

    第7章 甲状腺疾患
    A 甲状腺機能低下症
     1 先天性甲状腺機能低下症
     2 新生児一過性甲状腺機能低下症
     3 中枢性甲状腺機能低下症
     4 後天性甲状腺機能低下症
     5 粘液水腫性昏睡
    B 甲状腺中毒症
     1 Basedow病
     2 甲状腺クリーゼ
     3 中毒性結節性甲状腺腫
     4 無痛性甲状腺炎
     5 新生児甲状腺機能亢進症
     6 新生児Basedow病
    C 甲状腺炎
     1 亜急性甲状腺炎
     2 急性化膿性甲状腺炎
    D 自己免疫性甲状腺疾患の妊娠前・中の管理
    E 甲状腺ホルモン不応症
    F 甲状腺ホルモン代謝異常症（MCT8異常症）
    G 甲状腺腫瘍（甲状腺結節）

    第8章 カルシウムとビタミンD関連疾患
    A 新生児のカルシウム代謝異常
     1 新生児の低カルシウム血症
     2 新生児の高カルシウム血症
     3 未熟児代謝性骨疾患（未熟児骨減少症，未熟児くる病）
    B 低カルシウム血症
    C 副甲状腺機能低下症
    D 偽性副甲状腺機能低下症（PHP）
    E くる病
     1 ビタミンD欠乏性くる病
     2 低リン血症性くる病
     3 その他のくる病
      1．ビタミンD依存性くる病1型
      2．ビタミンD依存性くる病2型
      3．ビタミンD依存性くる病3型
      4．肝性くる病
      5．慢性腎臓病に伴う骨・ミネラル代謝異常
    F 高カルシウム血症
    G 副甲状腺機能亢進症
    H 骨系統疾患
     1 骨形成不全症
     2 低ホスファターゼ症

    第9章 糖代謝異常症
    A 糖尿病
     1 1型糖尿病
     2 2型糖尿病
     3 若年性成人発症糖尿病（MODY）
     4 ミトコンドリア遺伝子異常による糖尿病
     5 インスリン作用伝達機構に関与する遺伝子異常による糖尿病
     6 新生児糖尿病
     7 他の疾患・条件に伴う糖尿病
    B 低血糖症
     1 先天性高インスリン血症
     2 インスリノーマ
     3 ケトン性低血糖症
    C 糖尿病の妊娠管理
    D 糖尿病母体から出生した新生児

    第10章 肥満・脂質代謝異常症
    A 肥満とメタボリックシンドロームの治療
    B 脂質異常症

    第11章 尿細管障害
    A 腎尿細管性アシドーシス
     1 遠位型RTA
     2 近位型RTA
    B Bartter症候群とGitelman症候群
    C 偽性低アルドステロン症
     1 偽性低アルドステロン症1型（PHA 1）
     2 偽性低アルドステロン症2型（PHA 2）
     3 偽性低アルドステロン症3型（PHA 3，二次性偽性低アルドステロン症）

    第12章 内分泌異常に関連するその他の疾患
    A 摂食障害
    B 小児がん経験者（CCS）
    C 骨粗鬆症

    ■（再掲）内分泌救急対応

    ■附録
    A 本書に掲載した医薬品一覧表
    B 横断的標準身長・体重曲線
     1 横断的標準身長・体重曲線
     2 Turner症候群成長曲線
     3 Noonan症候群成長曲線
     4 軟骨無形成症成長曲線
    C BMIパーセンタイル曲線
    D 肥満度判定曲線
    E 標準体重
     1 性別・身長別標準体重計算式
     2 性別・年齢別・身長別標準体重（5歳以降）計算式
    F 身長・体重から体表面積を算出するノモグラム
     1 乳幼児用（身長40～120 cm）
     2 学童・成人用（身長120～190 cm）
    G 日本人の食事摂取基準
     1 推定エネルギー必要量（kcal/日）
     2 年齢別・性別の食事摂取基準（目安量または推奨量）
     3 日本人の食事摂取基準（2020年版）策定検討会報告書
    H 日本人小児の体格の評価

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 成長障害

P.9 掲載の参考文献
1) 厚生労働科学研究費補助金難治性疾患等政策研究事業「間脳下垂体機能障害に関する調査研究」班(編):成長ホルモン分泌不全性低身長症の診断と治療の手引き(平成30年度改訂). 日内分泌会誌 95(Suppl.):31-34, 2019 https://www.jstage.jst.go.jp/article/endocrine/95/S.May/95_1/_pdf/-char/ja
 
2) 成長科学協会:成長ホルモン剤適正使用推進事業. 小児成長ホルモン治療適応判定. 成長ホルモン分泌不全性低身長症. https://www.fgs.or.jp/business/growth_hormone/treatment_decision/growth_hormone_short_stature/
 
3) 田中敏明:成長ホルモン分泌不全性低身長症(GHD). 横谷 進, 他(編), 専門医による新小児内分泌疾患の治療. 改訂第2版, 診断と治療社, 2-13, 2017
 
4) 小児慢性特定疾病情報センター:小児慢性特定疾病における成長ホルモン治療の認定について https://www.shouman.jp/assist/hormone/
 
5) 田中敏章, 他:低身長児の思春期における成人身長の予測法(Growth Potential II 法). 日成長会誌 15:17-22, 2009
Medical*Online
6) Thodberg HH:BoneXpert with focus on the introduction in Japan. 日成長会誌 19:91-95, 2013
 
7) 横谷 進:成長ホルモン療法における有害事象. ホルモンと臨 48:457-468, 2000
 
8) Savendahl L, et al.:Long-term mortality after childhood growth hormone treatment:the SAGhE cohort study. Lancet Diabetes Endocrinol 8:683-692, 2020
PubMed
9) Tanaka T, et al.:Effect of growth hormone(GH) treatment on adult height in patients with GH deficiency:the Japanese cohort from the GeNeSIS observational study. 日成長会誌 26:28-37, 2020
 
10) 厚生労働科学研究費補助金難治性疾患等政策研究事業「間脳下垂体機能障害に関する調査研究」班(編):成長ホルモン分泌不全症の小児期から成人期への移行・トランジションの診断と治療の手引き(平成30年度作成). 日内分泌会雑 95(Suppl.):35, 2019 https://www.jstage.jst.go.jp/article/endocrine/95/S.May/95_1/_pdf/-char/ja
 
11) 日本臨床栄養学会(編):亜鉛欠乏症の診療指針 2018. http://jscn.gr.jp/pdf/aen2018.pdf
 
12) 田中敏章, 他:成長ホルモン分泌不全性低身長症における成長ホルモンによる前思春期の治療開始年齢別治療効果. 日成長会誌 16:23-29, 2010
Medical*Online
13) 小川正道, 他:特発性成長ホルモン分泌不全性低身長症における治療による成人身長. 日小児会誌 116:979-984, 2012
 
P.11 掲載の参考文献
1) Gravholt CH, et al.:Clinical practice guidelines for the care of girls and women with Turner syndrome:proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur J Endocrinol 177:G1-G70, 2017
PubMed
2) 日本小児内分泌学会薬事委員会:ターナー症候群におけるエストロゲン補充療法ガイドライン. 日小児会誌 112:1048-1050, 2008
 
3) 望月貴博, 他:成長ホルモン治療中のターナー症候群におけるエストロゲン補充療法の治療実態と開始時期の基準について. 日成長会誌 22:43-47, 2016
Medical*Online
4) Mohamed S, et al.:Oxandrolone for growth hormone-treated girls aged up to 18 years with Turner syndrome. Cochrane Database Syst Rev 2019, 2019
PubMed
5) Isojima T, et al.:Proposal of new auxological standards for Japanese girls with turner syndrome. Clin Pediatr Endocrinol 19:69-82, 2010
 
6) 望月貴博, 他:成人Turner症候群の長期フォローアップについて本人・家族の会アンケートによる現状調査. 日小児会誌 114:43-47, 2010
 
7) 田中敏章, 他:ターナー症候群の0.35mg/kg/週による成長ホルモン治療後の成人身長-TRC 共同研究-. 日成長会誌 24:64-70, 2018
Medical*Online
8) Hasegawa Y, et al.:Gradually increasing ethinyl estradiol for Turner syndrome may produce good final height but not ideal BMD. Endocr J 64:221-227, 2017
PubMed
P.13 掲載の参考文献
1) Ornitz DM, et al.:Fibroblast growth factor signaling in skeletal development and disease. Genes Dev 29:1463-1486, 2015
PubMed
2) Kubota T, et al.:Clinical Practice Guidelines for Achondroplasia. Clin Pediatr Endocrinol 29:25-42, 2020
PubMed
3) 難病情報センター:軟骨無形成症(指定難病 276). http://www.nanbyou.or.jp/entry/4571
 
4) 成長科学協会:成長ホルモン剤適正使用推進事業. 小児成長ホルモン治療適応判定. 軟骨異栄養症ヒト成長ホルモン治療適応基準. https://www.fgs.or.jp/business/growth_hormone/treatment_decision/osteochondrodystrophy/chart.html
 
5) Tanaka H, et al.:Effect of growth hormone therapy in children with achondroplasia:growth pattern, hypothalamic-pituitary function, and genotype. Eur J Endocrinol 138:275-280, 1998
PubMed
6) Harada D, et al.:Final adult height in long-term growth hormone-treated achondroplasia patients. Eur J Pediatr 176:873-879, 2017
PubMed
7) Massart F, et al.:Height outcome of short children with hypochondroplasia after recombinant human growth hormone treatment:a meta-analysis. Pharmacogenomics 16:1965-1973, 2015
PubMed
8) Kim SJ, et al.:The etiology of short stature affects the clinical outcome of lower limb lengthening using external fixation. A systematic review of 18 trials involving 547 patients. Acta Orthop 85:181-186, 2014
PubMed
9) Hoover-Fong J, et al.:Lifetime impact of achondroplasia:Current evidence and perspectives on the natural history. Bone 146:115872, 2021
PubMed
10) Hoover-Fong J, et al.:Health supervision for people with achondroplasia. Pediatrics 145:e20201010, 2020
PubMed
11) Legeai-Mallet L, et al.:Novel therapeutic approaches for the treatment of achondroplasia. Bone 141:115579, 2020
PubMed
12) Adam MP, et al.(eds):GeneReviews[Internet]. University of Washington, Seattle, 1993-2021
 
P.15 掲載の参考文献
1) Noonan JA:Hypertelorism with Turner phenotype. A new syndrome with associated congenital heart disease. Am J Dis Child 116:373-380, 1968
PubMed
2) Romano AA, et al.:Noonan syndrome:clinical features, diagnosis, and management guidelines. Pediatrics 126:746-759, 2010
PubMed
3) Tohoku University School of Medicine:The RAS/MAPK Syndrome Homepage. http://www.medgen.med.tohoku.ac.jp/rasmapk_j/rasmapk/
 
4) 厚生労働科学研究費補助金難治性疾患等克服研究事業(難治性疾患克服研究事業)「分子診断に基づくヌーナン症候群の診断・治療ガイドライン作成と新規病因遺伝子探索」研究班(研究代表者 松原洋一):「分子診断に基づくヌーナン症候群の診断・治療ガイドライン作成と新規病因遺伝子探索」平成23年度-24年度総合研究報告書. 8, 2013
 
5) Giacomozzi C, et al.:The impact of growth hormone therapy on adult height in noonan syndrome:a systematic review. Horm Res Paediatr 83:167-176, 2015
 
6) 日本小児内分泌学会:ヌーナン症候群における低身長に対するGH治療実施上の注意. 2020年5月25日改訂. 2020 http://jspe.umin.jp/medical/files/guide20200917.pdf
 
P.17 掲載の参考文献
1) Deal CL, et al.:GrowthHormone Research Society workshop summary:consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. J Clin Endocrinol Metab 98:E1072-E1087, 2013
PubMed
2) Passone CGB, et al.:Growth hormone treatment in Prader Willi syndrome patients:systematic review and meta-analysis. BMJ Paediatr Open 4:e000630, 2020
PubMed
3) Sanchez-Ortiga R, et al.:Effects of recombinant human growth hormone therapy in adults with Prader-Willi syndrome:a meta-analysis. Clin Endocrinol(Oxf)77:86-93, 2012
PubMed
4) Kuppens RJ, et al.:Beneficial Effects of GH in Young Adults With Prader-Willi Syndrome:A 2-Year Crossover Trial. J Clin Endocrinol Metab 101:4110-4116, 2016
PubMed
5) Morales JS, et al.:Physical exercise and Prader-Willi syndrome:A systematic review. Clin Endocrinol (Oxf) 90:649-661, 2019
PubMed
6) Angulo MA, et al.:Prader-Willi syndrome:a review of clinical, genetic, and endocrine findings. J Endocrinol Invest 38:1249-1263, 2015
PubMed
P.18 掲載の参考文献
1) Karlberg J, et al.:Growth in full-term small-for gestational-age infants from birth to final height. Pediatr Res 38:733-739, 1995
PubMed
2) 日本小児内分泌学会, 他:SGA性低身長症におけるGH治療のガイドライン. 日小児会誌 111:641-646, 2007
 
3) Horikawa R, et al.:The long-term safety and effectiveness of growth hormone treatment in Japanese children with short stature stature born small for gestational age. Clin Pediatr Endocrinol 29:159-171, 2020
 
4) Tanaka T, et al.:Long-term safety and efficiency of daily recombinant human growth hormone treatment in Japanese short children born small for getational age:final report from an open and multi-center study. Clin Pediatr Endocrinol 27:145-157, 2018
 
5) Yokoya S, et al.:Efficacy and safety of growth hormone treatment in Japanese children with small-for-gestational age short stature in accordance with Japanse guidelines. Clin Pediatr Endocrinol 27:225-234, 2018
 
P.20 掲載の参考文献
1) CKD診療ガイド・ガイドライン改訂委員会:小児CKD. 日本腎臓学会(編), エビデンスに基づくCKD診療ガイドライン2018. 東京医学社, 58-74, 2018
 
2) 濱崎祐子:小児慢性腎不全と成長障害. 日本小児腎臓病学会(編), 小児腎臓病学. 改訂第2版, 診断と治療社, 402-405, 2017
 
3) Drube J, et al.:Clinical practice recommendations for growth hormone treatment in children with chronic kidney disease. Nat Rev Nephrol 15:577-589, 2019
PubMed
4) Haffner D, et al.:Pubertal development in children with chronic kidney disease. Pediatr Nephrol 32:949-964, 2017
PubMed
5) 日本腎臓学会(編):エビデンスに基づくCKD診療ガイドライン2018. https://cdn.jsn.or.jp/data/guideline-20180629.pdf
 
6) 東京都立小児総合医療センター腎臓内科:CKD合併症の管理. 東京都立小児総合医療センター腎臓内科(編), 小児のCKD/AKI実践マニュアル-透析・移植まで-. 診断と治療社, 116-156, 2013
 
P.21 掲載の参考文献
1) Woods KA, et al.:Effects of insulin-like growth factor I(IGF-I)therapy on body composition and insulin resistance in IGF-I gene deletion. J Clin Endocrinol Metab 85:1407-1411, 2000
 
2) Guevara-Aguirre J, et al.:Treatment of growth failure in the absence of GH signaling:The Ecuadorian experience. Growth Horm IGF Res 38:53-58, 2018
PubMed
3) Chernausek SD, et al.:Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab 92:902-910, 200
PubMed
4) Walenkamp MJE:Single gene mutations causing SGA. Best Prac Res Clin Endocrinol Metab 22:433-446, 2008
 
5) Walenkamp MJE, et al.:Phenotypic features and response to GH treatment of patients with a molecular defect of the IGF-1 receptor. J Clin Endocrinol Metab 104:3157-3171, 2019
PubMed
P.22 掲載の参考文献
1) Rappold G, et al.:Genotypes and phenotypes in children with short stature:clinical indicators of SHOX haploinsufficiency. J Med Genet 44:306-313, 2007
PubMed
2) E Rao, et al.:Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome. Nat Genet 16:54-63, 1997
 
3) Cormier-Daire V, et al.:SHOX gene mutations and deletions in dyschondrosteosis or Leri-Weill syndrome. Acta Paediatr Suppl 88:55-59, 1999
 
P.24 掲載の参考文献
1) 田中敏章, 他:小城成長研究データに基づく日本人男子の成長 第1編. 生物学的定義に近似した成長学的な思春期開始の基準値の作成. 日成長会誌 26:16-21, 2020
Medical*Online
2) 田中敏章, 他:縦断的検討による女児の思春期の成熟と初経年齢の標準化. 日小児会誌 109:1232-1242, 2005
 
3) 田中敏章, 他:成人低身長になる機序:低身長思春期発来. 日成長会誌 17:17-23, 2011
Medical*Online
4) 田中敏章, 他:低身長児の思春期における成人身長の予測法(Growth Potential II 法). 日成長会誌 15:17-22, 2009
Medical*Online
5) Tanaka T:Combination treatment of GH and LHRH analog to increase pubertal growth for GHD children who enter puberty with short stature. Clin Pediatr Endocrinol 14(Suppl.):7-16, 2005
 
6) 内木康博, 他:思春期男子における蛋白同化ホルモンの成長促進効果. 日小児臨薬理会誌 18:143-146, 2005
 
7) Tanaka T, et al.:The effect of combination treatment of growth hormone and anabolic steroid hormone on adult height in boys with growth hormone deficiency. J Jpn Ass Hum Auxo 23:21-30, 2017
 
8) Tanaka T, et al.:Combined treatment with gonadotropin-releasing hormone analog and anabolic steroid hormone increased pubertal height gain and adult height in boys with early puberty for height. Clin Pediatr Endocrinol 21:35-43, 2012
PubMed
9) 岸 健太郎, 他:LHRHアナログ単独治療により思春期早発症女児の成人身長は改善するか? 日成長会誌 25:13-21, 2019
Medical*Online
P.25 掲載の参考文献
1) Lauffer P, et al.:Towards a Rational and Efficient Diagnostic Approach in Children Referred for Tall Stature and/or Accelerated Growth to the General Paediatrician. Horm Res Paediatr 91:293-310, 2019
PubMed
2) Edouard T:What treatment for a child with tall stature? Ann Endocrinol(Paris)78:104-105, 2017
PubMed
3) Leung AKC, et al.:Tall Stature in Children. Adv Pediatr 66:161-176, 2019
PubMed
田中敏章:高身長. 横谷 進, 他(編), 専門医による新小児内分泌疾患の治療. 改訂第2版, 診断と治療社, 25-27, 2017
 

第2章 視床下部・下垂体障害による内分泌疾患

P.29 掲載の参考文献
1) Vallette-Kasic S, et al.:Congenital isolated adrenocorticotropin deficiency:an underestimated cause of neonatal death, explained by TPIT gene mutations. J Clin Endocrinol Metab 90:1323-1331, 2005
PubMed
2) Binder G, et al.:Rational approach to the diagnosis of severe growth hormone deficiency in the newborn. J Clin Endocrinol Metab 95:2219-2226, 2010
 
3) Kohva E, et al.:Treatment of gonadotropin deficiency during the first year of life:long-term observation and outcome in five boys. Hum Reprod 34:863-871, 2019
PubMed
P.31 掲載の参考文献
1) 間部裕代:間脳-下垂体近傍腫瘍. 日本小児内分泌学会(編), 小児内分泌学. 改訂3版, 診断と治療社, 238-241, 2022
 
2) Louis DN, et al.:The 2021 WHO Classification of CNS Tumors of the Central Nervous System:a summary. Neuro Oncol 23:1231-1251, 2021
PubMed
3) 日本脳腫瘍学会(編), 日本脳神経外科学会(監):2021年版脳腫瘍診療ガイドライン:小児脳腫瘍編. https://www.jsn-o.com/guideline/index.html
 
4) 川俣貴一, 他:長期機能予後からみた頭蓋咽頭腫に対する外科治療戦略. 日内分泌会誌 94(Suppl.):5-6, 2018
 
5) 小川加奈, 他:視床下部過誤腫の6症例の検討:頭部MRI所見と臨床症状. 脳と発達 46:419-423, 2014
Medical*Online
6) 北条雅人, 他:下垂体卒中の診断と治療. 日内分泌会誌 86(Suppl.):25-26, 2010
 
7) Briet C, et al.:Pituitary Apoplexy. Endocr Rev 36:622-645, 2015
PubMed
8) Ohata H, et al.:Pituitary apoplexy in a puberal child:A case report and review of the literature. Interdisciplinary Neurosurgery 25:101160, 2021
 
9) 杉山一彦, 他:髄芽腫臨床を理解するための12項目. 脳神外ジャーナル 20, 363-371, 2011
 
P.33 掲載の参考文献
1) 片上秀喜:リンパ球性下垂体炎. 日本内分泌学会(編), 内分泌代謝科専門医研修ガイドブック. 診断と治療社, 251-256, 2018
 
2) 島津 章:自己免疫性視床下部下垂体炎. 別冊日本臨牀内分泌症候群I-その他の内分泌疾患を含めて-. 第3版, 日本臨牀社, 35-41, 2018
 
3) Mirocha S, et al.:T regulatory cells distinguish two types of primary hypophysitis. Clin Exp Immunol 155:403-411, 2009
PubMed
4) 厚生労働科学研究費補助金難治性疾患等政策研究事業「間脳下垂体機能障害に関する調査研究」班(編):自己免疫性視床下部下垂体炎の診断と治療の手引き(平成30年度改訂). 日内分泌会誌 95(Suppl.), 54-58, 2019 https://www.jstage.jst.go.jp/article/endocrine/95/S.May/95_1/_pdf/-char/ja
 
5) Iwama S, et al.:Rabphilin-3A as a targeted Autoantigen in Lymphocytic Infundibuloneurohypophysitis. J Clin Endocrinol Metab 100:E946-E954, 2015
PubMed
P.34 掲載の参考文献
1) Gubbi S, et al.:Hypophysitis:An update on the novel forms, diagnosis and management of disorders of pituitary inflammation. Best Pract Res Clin Endocrinol Metab 33:101371, 2019
PubMed
2) Caturegli P, et al.:Autoimmune hypophysitis. Endocr Rev 26:599-614, 2005
PubMed
3) Joshi MN, et al.:MECHANISMS IN ENDOCRINOLOGY:Hypophysitis:diagnosis and treatment. Eur J Endocrinol 179:R151-R163, 2018
 
4) 片上秀喜:リンパ球性下垂体炎. 日本内分泌学会(編), 内分泌代謝科専門医研修ガイドブック. 診断と治療社, 251-256, 2018
 
5) 厚生労働科学研究費補助金難治性疾患等政策研究事業「間脳下垂体機能障害に関する調査研究」班(編):間脳下垂体機能障害の診断と治療の手引き(平成30年度改訂). 日内分泌会誌 95(Suppl.):1-60, 2019 https://www.jstage.jst.go.jp/article/endocrine/95/S.May/95_1/_pdf/-char/ja
 
6) Takagi H, et al.:Diagnosis and treatment of autoimmune and IgG4-related hypophysitis:clinical guidelines of the Japan Endocrine Society. Endocr J 67:373-378, 2020
PubMed
7) Haupt R, et al.:Permanent consequences in Langerhans cell histiocytosis patients:a pilot study from the Histiocyte Society-Late Effects Study Group. Pediatr Blood Cancer 42:438-444, 2004
 
P.35 掲載の参考文献
1) Inoshita N, et al.:The 2017 WHO classification of pituitary adenoma:overview and comments. Brain Tumor Pathol 35:51-56, 2018
PubMed
2) 厚生労働科学研究費補助金難治性疾患等政策研究事業「間脳下垂体機能障害に関する調査研究」班(編):間脳下垂体機能障害の診断と治療の手引き(平成30年度改訂). 日内分泌会誌 95(Suppl.):ii, 2019 https://www.jstage.jst.go.jp/article/endocrine/95/S.May/95_1/_pdf/-char/ja
 
3) 厚生労働科学研究費補助金難治性疾患等政策研究事業「間脳下垂体機能障害に関する調査研究」班(編):下垂体TSH産生腫瘍の診断と治療の手引き(平成30年度改訂). 日本内分泌会誌 95(Suppl.):29-30, 2019 https://www.jstage.jst.go.jp/article/endocrine/95/S.May/95_1/_pdf/-char/ja
 
4) 竹下 彰:TSH産生下垂体腺腫. 竹内靖博, 他(編著), 虎の門病院内分泌 クリニカルプラクティス～外来・入院からフォローアップまで. クリニコ出版, 100-106, 2020
 
P.37 掲載の参考文献
1) 厚生労働科学研究費補助金難治性疾患等政策研究事業「間脳下垂体機能障害に関する調査」研究班(編):高プロラクチン(PRL)血症の診断と治療の手引き(平成30年度改訂). 日内分泌会誌 95(Suppl.):12-14, 2019 https://www.jstage.jst.go.jp/article/endocrine/95/S.May/95_1/_pdf/-char/ja
 
2) 辰島啓太:プロラクチノーマ～高プロラクチン血症. 竹内靖博, 他(編著), 虎の門病院内分泌 クリニカルプラクティス～外来・入院からフォローアップまで. クリニコ出版, 76-85, 2020
 
3) Melmed S, et al.:Diagnosis and treatment of hyperprolactinemia:an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:273-288, 2011
PubMed
4) Salenave S, et al.:Macroprolactinomas in children and adolescents:factors associated with the response to treatment in 77 patients. J Clin Endocrinol Metab 100:1177-1186, 2015
PubMed
5) Tichomirowa MA, et al.:High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. Eur J Endocrinol 165:509-515, 2011
PubMed
6) Ma Q, et al.:The chance of permanent cure for micro-and macroprolactinomas, medication or surgery? A systematic review and meta-analysis. Front Endocrinol(Lausanne)9:636, 2018
PubMed
7) Zamanipoor Najafabadi AH, et al.:Surgery as a Viable Alternative First-Line Treatment for Prolactinoma Patients. A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab 105:e32-e41, 2020
PubMed
P.39 掲載の参考文献
1) Tichomirowa MA, et al.:High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. Eur J Endocrinol 165:509-515. 2011
PubMed
2) 厚生労働科学研究費補助金難治性疾患等政策研究事業「間脳下垂体機能障害に関する調査研究」班:先端巨大症および下垂体性巨人症の診断と治療の手引き(平成30年度改訂). 日内分泌会誌 95(Suppl.):1-7, 2019 https://www.jstage.jst.go.jp/article/endocrine/95/S.May/95_1/_pdf/-char/ja
 
3) 竹下 彰:先端巨大症(アクロメガリー). 竹内靖博, 他(編著), 虎の門病院内分泌 クリニカルプラクティス～外来・入院からフォローアップまで. クリニコ出版, 60-75, 2020
 
4) Melmed S, et al.:A Consensus Statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol 14:552-561. 2018
PubMed

第3章 水・電解質代謝障害

P.44 掲載の参考文献
1) Di Iorgi N, et al.:Diabetes insipidus--diagnosis and management. Horm Res Paediatr 77:69-84, 2012
PubMed
2) 伊藤純子:中枢性尿崩症. 日本小児内分泌学会(編), 小児内分泌学. 改訂第3版, 診断と治療社, 264-266, 2022
 
3) Imura H, et al.:Lymphocytic infundibuloneurohypophysitis as a cause of central diabetes insipidus. N Engl J Med 329:683-689, 1993
PubMed
4) Maghnie M, et al.:Central diabetes insipidus in children and young adults. N Engl J Med 343:998-1007, 2000
 
5) 厚生労働科学研究費補助金難治性疾患等政策研究事業「間脳下垂体機能障害に関する調査研究」班(編):バソプレシン分泌低下症(中枢性尿崩症)の診断と治療の手引き(平成30年度改訂). 日内分泌会誌 95(Suppl.):15-16, 2019 https://www.jstage.jst.go.jp/article/endocrine/95/S.May/95_1/_pdf/-char/ja
 
6) 瀧浦俊彦, 他:中枢性尿崩症患者における小児多尿基準の検討. 日内分泌会誌 91:338, 2015
Medical*Online
7) 椙村益久, 他:バゾプレシン. 臨床検査 52(増刊):1208-1211, 2008
 
8) 菅原 明 他:中枢性尿崩症. 成瀬光栄, 他(編), 内分泌代謝専門医ガイドブック. 改訂第3版, 診断と治療社, 119-121, 2012
 
9) Arima H, et al.:Efficacy and safety of desmopressin orally disintegrating tablet in patients with central diabetes insipidus:results of a multicenter open-label dose-titration study. Endocr J 60:1085-1094. 2013
PubMed
10) 星野雄介, 他:デスモプレシン口腔内崩壊錠を用いた新生児中枢性尿崩症の治療経験. 日新生児成育医会誌 31:74-77, 2019
 
11) 伊藤純子:脳腫瘍術後の水・電解質管理. 日本小児内分泌学会(編), 小児がん内分泌診療の手引き.診断と治療社, 45-49, 2021
 
12) 伊藤純子:尿崩症. 小児内科 53:603-607, 2021
Medical*Online
P.45 掲載の参考文献
1) Marques P, et al.:Transient diabetes insipidus in pregnancy. Endocrinol Diabetes Metab Case Rep 2015:150078, 2015
PubMed
2) Monson JP, et al.:Osmoregulatory adaptation in pregnancy and its disorders. J Endocrinol 132:7-9, 1992
PubMed
3) Oiso Y:Transient diabetes insipidus during pregnancy. Intern Med 42:459-460, 2003
PubMed
4) Lindheimer MD, et al.:Osmoregulation, the secretion of arginine vasopressin and its metabolism during pregnancy. Eur J Endocrinol 132:133-143, 1995
PubMed
5) Kalelioglu I, et al.:Transient gestational diabetes insipidus diagnosed in successive pregnancies:review of pathophysiology, diagnosis, treatment, and management of delivery. Pituitary 10:87-93, 2007
PubMed
6) Refardt J, et al.:Diabetes insipidus in pregnancy:how to advice the patient? Minerva Endocrinol 43:458-464. 2018
PubMed
7) 天野麻子, 他:術後に尿崩症と診断された緊急帝王切開の麻酔経験. 麻酔 52:158-161, 2003
Medical*Online
8) 中島 彰, 他:妊娠後期に尿崩症を合併した1例. 臨婦産 62:1229-1232, 2008
 
9) 秦 利之, 他:尿崩症. 産と婦 65:1613-1617, 1998
Medical*Online
10) Oiso Y, et al.:Clinical review:Treatment of neurohypophyseal diabetes insipidus. J Clin Endocrinol Metab 98:3958-3967, 2013
PubMed
P.46 掲載の参考文献
1) Robertson GL, et al.:Neurogenic disorders of osmoregulation. Am J Med 72:339-353, 1982
PubMed
2) Welt LG:Hypo-and hypernatremia. Ann Intern Med 56:161-164, 1962
PubMed
3) Suneja M, et al.:Essential hypernatremia:evidence of reset osmostat in the absence of demonstrable hypothalamic lesions. Am J Med Sci 347:341-342. 2014
PubMed
4) Hiyama TY, et al.:Autoimmunity to the sodium-level sensor in the brain causes essential hypernatremia. Neuron 66:508-522, 2010
 
5) 横谷 進:本態性高ナトリウム血症(口渇中枢障害を伴う高ナトリウム血症). 専門医による新小児内分泌疾患の治療. 田苗綾子, 他(編著), 診断と治療社, 49-51, 2007
 
6) Nandi M, et al.:Successful treatment of hypernatremic thirst deficiency with chlorpropamide. Clin Nephrol 10:90-95, 1978
PubMed
7) Crowley RK, et al.:Clinical insights into adipsic diabetes insipidus:a large case series. Clin Endocrinol (Oxf) 66:475-482, 2007
PubMed
P.49 掲載の参考文献
1) Bockenhauer D, et al.:Pathophysiology, diagnosis and management of nephrogenic diabetes insipidus. Nat Rev Nephrol 11:576-588, 2015
PubMed
2) Kavanagh C, et al.:Nephrogenic Diabetes Insipidus. Pediatr Clin North Am 66:227-234, 2019
PubMed
3) Stoff JS, et al.:Indomethacin impairs water diuresis in the DI rat:role of prostaglandins independent of ADH. Am J Physiol 241:F231-F237, 1981
PubMed
4) Libber S, et al.:Treatment of nephrogenic diabetes insipidus with prostaglandin synthesis inhibitors. J Pediatr 108:305-311, 1986
PubMed
5) Bockenhauer D, et al.:Nephrogenic diabetes insipidus. Curr Opin Pediatr 29:199-205, 2017
PubMed
6) van Lieburg AF, et al.:Clinical presentation and follow-up of 30 patients with congenital nephrogenic diabetes insipidus. J Am Soc Nephrol 10:1958-1964, 1999
PubMed
7) Lejarraga H, et al.:Long-term growth of children with nephrogenic diabetes insipidus. Pediatr Nephrol 23:2007-2012, 2008
PubMed
8) Sharma S, et al.:Long-term outcome in inherited nephrogenic diabetes insipidus. Clin Kidney J 12:180-187, 2019
PubMed
9) Lopez-Garcia SC, et al.:Treatment and long-term outcome in primary nephrogenic diabetes insipidus. Nephrol Dial Transplant 2020 Dec 26; gfaa243.[Epub ahead of print]
 
P.51 掲載の参考文献
1) 水野晴夫:乳幼児習慣性多飲多尿. 日本小児内分泌学会(編), 小児内分泌学. 改訂第3版, 診断と治療社, 277-278, 2022
 
2) Kohn B, et al.:Hysterical polydipsia (compulsive water drinking) in children. Am J Dis Child 130:210-212, 1976
PubMed
3) Accardo P, et al.:Excessive water drinking. A marker of caretaker interaction disturbance. Clin Pediatr(Phila) 28:416-418, 1989
PubMed
4) Arieff AI, et al.:Fatal child abuse by forced water intoxication. Pediatrics 103:1292-1295, 1999
PubMed
5) Terai K, et al.:Excessive water drinking behavior in autism. Brain Dev 21:103-106, 1999
PubMed
6) Linquette M, et al.:Acute water intoxication from compulsive drinking. Br Med J 2:365, 1973
PubMed
7) 小林朋子, 他:無熱性けいれんを主訴に来院した水中毒の2症例-乳幼児の水分補給指導の重要性-. 小児保健研究 65:577-584, 2006
Medical*Online
P.53 掲載の参考文献
1) 有阪 治:低浸透圧症候群. 日本小児内分泌学会(編), 小児内分泌学. 改訂第3版, 診断と治療社, 278-284, 2022
 
2) Moritz ML:Syndrome of inappropriate antidiuresis. Pediatr Clin North Am 66:209-226, 2019
PubMed
3) 厚生労働科学研究費補助金難治性疾患等政策研究事業「間脳下垂体機能障害に関する調査研究」班(編):バソプレシン分泌過剰症(SIADH)の診断と治療の手引き(平成30年度改訂). 日内分泌会誌 95 (Suppl.):18-20, 2019 https://www.jstage.jst.go.jp/article/endocrine/95/S.May/95_1/_pdf/-char/ja
 
4) Repaske DR, et al.:Disorders of water balance. In:Brook CGD, et al.(eds), Brook's Clinical Pediatric Endocrinology. 6th ed, Wiley-Blackwell, Oxford, 343-395, 2009
 
5) Srivasta A, et al.:Disorders of posterior pituitary. In:Sperling MA(ed), Sperling Pediatric Endocrinology. 5th ed, Elsevier, Philadelphia, 357-394, 2021
 
6) Tuli G, et al.:Tolvaptan treatment in children with chronic hyponatremia due to inappropriate antidiuretic hormone secretion:A report of three cases. J Clin Res Pediatr Endocrinol 9:288-292, 2017
 
7) 依藤 亨, 他:水・電解質異常. 日本小児内分泌学会(編), 小児がん内分泌診療の手引き. 診断と治療社, 98-103, 2021
 
8) 小児慢性特定疾病情報センター:中枢性塩喪失症候群. https://www.shouman.jp/disease/details/05_09_014/
 
9) Maesaka JK, et al.:Evolution and evolving resolution of controversy over existence and prevalence of cerebral/renal salt wasting. Curr Opin Nephrol Hypertens 29:213-220, 2020
PubMed
10) Taplin CE, et al.:Fludrocortisone therapy in cerebral salt wasting. Pediatrics 118:e1904-e1908, 2006
PubMed
11) Taylor P, et al.:Cerebral salt wasting following traumatic brain injury. Endocrinol Diabetes Metab Case Rep 2017:ID16-0142, 2017
 
P.56 掲載の参考文献
1) 日本夜尿症学会(編):夜尿症診療ガイドライン 2021. 診断と治療社, 2021
 
2) 金子一成:小児科医が知っておきたい夜尿症のみかた. 南山堂, 2018
 
3) 西 美和:多飲・多尿・頻尿. 小児診療 83(Suppl.):152-156, 2020
 
4) 西 美和:頻尿, 昼間遺尿(昼間のおもらし). 小児臨 72(Suppl.):1208-1212, 2019
 
5) 伊藤純子:見逃してはいけない症例-夜尿症といわれていた糖尿病・脳腫瘍. 小児内科 52:1585-1586, 2020
Medical*Online
6) 伊藤純子:中枢性尿崩症. 日本小児内分泌学会(編), 小児内分泌学. 改訂第3版, 診断と治療社, 264-268. 2022
 
7) 川野早紀子, 他:頭部CTや血管造影 検査で縮小したGerminomaの2例. 第113回日本小児科学会島根地方会, 2021年6月
 

第4章 思春期発来異常をきたす疾患

P.60 掲載の参考文献
1) Teilmann G, et al.:Prevalence and incidence of precocious pubertal development in Denmark:an epidemiologic study based on national registries. Pediatrics 116:1323-1328, 2005
PubMed
2) Carel JC, et al.:Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 123:e752-e762, 2009
PubMed
3) Melmed S, et al.:Williams Textbook of Endocrinology. 12th ed, Saunders (Elsevier), Pliladelphia, 2011
 
4) 厚生労働科学研究費補助金難治性疾患等政策研究事業「間脳下垂体機能障害に関する調査研究」班(編):中枢性思春期早発症の診断と治療の手引き(平成30年度改訂). 日内分泌会誌 95(Suppl.):25-28, 2019 https://www.jstage.jst.go.jp/article/endocrine/95/S.May/95_1/_pdf/-char/ja
 
5) Bangalore Krishna K, et al.:Use of Gonadotropin-Releasing Hormone Analogs in Children:Update by an International Consortium. Horm Res Paediatr 91:357-372, 2019
 
6) Herter LD, et al.:Ovarian and uterine findings in pelvic sonography:comparison between prepubertal girls, girls with isolated thelarche, and girls with central precocious puberty. J Ultrasound Med 21:1237-1246;quiz 1247-1248, 2002
 
7) Tanaka T, et al.:Results of long-term follow-up after treatment of central precocious puberty with leuprorelin acetate:evaluation of effectiveness of treatment and recovery of gonadal function. The TAP-144-SR Japanese Study Group on Central Precocious Puberty. J Clin Endocrinol Metab 90:1371-1376, 2005
 
P.62 掲載の参考文献
1) Shibata N, et al.:Peripheral precocious puberty in a girl with an intracranial hCG-producing tumor:case report and literature review. Endocr J 68:1463-1467, 2021
 
2) Kreher NC, et al.:Treatment of familial male-limited precocious puberty with bicalutamide and anastrozole. J Pediatr 149:416-420, 2006
PubMed
3) Reiter EO, et al.:Bicalutamide plus anastrozole for the treatment of gonadotropin-independent precocious puberty in boys with testotoxicosis:a phase II, open-label pilot study(BATT). J Pediatr Endocrinol Metab 23:999-1009, 2010
 
4) Lenz AM et al.:Bicalutamide and third-generation aromatase inhibitors in testotoxicosis. Pediatrics 126:e728-e733, 2010
PubMed
5) Leschek EW et al.:Effect of Antiandrogen, Aromatase Inhibitor, and Gonadotropin-releasing Hormone Analog on Adult Height in Familial Male Precocious Puberty. J Pediatr 190:229-235, 2017
PubMed
P.63 掲載の参考文献
1) Neyman A, et al.:Treatment of Girls and Boys with McCune-Albright Syndrome with Precocious Puberty-Update 2017. Pediatr Endocrinol Rev 15:136-141, 2017
PubMed
2) Schoelwer M, et al.:Treatment of Peripheral Precocious Puberty. Endocr Dev 29:230-239, 2016
PubMed
3) Javaid MK, et al.:Best practice management guidelines for fibrous dysplasia/McCune-Albright syndrome:a consensus statement from the FD/MAS international consortium. Orphanet J Rare Dis 14:139, 2019
 
4) Spencer T, et al.:The Clinical Spectrum of McCune-Albright Syndrome and Its Management. Horm Res Paediatr 92:347-356, 2019
PubMed
5) Majoor BC, et al.:Increased Risk of Breast Cancer at a Young Age in Women with Fibrous Dysplasia. J Bone Miner Res 33:84-90, 2018
 
P.64 掲載の参考文献
1) Papanikolaou A, et al.:Autonomous Ovarian Cysts in Prepubertal Girls. How Aggressive Should We Be? A Review of the Literature. J Pediatr Adolesc Gynecol 28:292-296, 2015
PubMed
P.65 掲載の参考文献
都 研一:内分泌疾患に伴う続発性思春期早発症. 日本小児内分泌学会(編), 小児内分泌学. 改訂第3版, 診断と治療社, 306-307, 2022
 
三善陽子, 他:性腺障害. 日本小児内分泌学会(編), 小児がん内分泌診療の手引き. 診断と治療社, 91-97, 2021
 
P.66 掲載の参考文献
都 研一:部分型思春期早発症. 日本小児内分泌学会(編), 小児内分泌学. 改訂第3版, 診断と治療社, 307-308, 2022
 
Garibaldi L, et al.:Incomplete(partial)precocious development. In:Kliegman RM, et al.(eds), Nelson Textbook of Pediatrics. 19th ed, Saunders(Elsevier), Philadelphia, 1893-1894, 2011
 
P.67 掲載の参考文献
1) 田中敏章, 他:縦断的検討による女児の思春期の成熟と初経年齢の標準化. 日小児会誌 109:1232-1242, 2005
 
2) Matsuo N:Skeletal and sexual maturation in Japanese children. Clin Pediatr Endocrinol 2 (Suppl. 1):1-4, 1993
 
3) 大山建司:思春期の生理学 二次性徴の発現. 日本小児内分泌学会(編), 小児内分泌学. 診断と治療社, 270-272, 2009
 
4) Dwyer AA, et al.:Congenital hypogonadotropic hypogonadism:implications of absent mini-puberty. Minerva Endocrinol 41:188-195, 2016
PubMed
5) 佐々木悟郎:性腺疾患-思春期早発症および遅発症, 性腺機能低下症-. 小児臨 71:933-939, 2018
Medical*Online
6) Stancampiano MR, et al.:Testosterone Therapy in Adolescent Boys:The Need for a Structured Approach. Horm Res Paediatr 92:215-228, 2019
PubMed
7) Wei C, et al.:Recent advances in the understanding and management of delayed puberty. Arch Dis Child 101:481-488, 2016
PubMed
P.71 掲載の参考文献
1) 厚生労働科学研究費補助金難治性疾患等政策研究事業「間脳下垂体機能障害に関する調査研究」班(編):ゴナドトロピン分泌低下症の診断と治療の手引き(平成30年度改訂). 日内分泌会誌 95(Suppl.):44-49, 2019 https://www.jstage.jst.go.jp/article/endocrine/95/S.May/95_1/_pdf/-char/ja
 
2) 小児慢性特定疾病情報センター:カルマン(Kallmann)症候群-診断の手引き. https://www.shouman.jp/disease/instructions/05_29_061/
 
3) Boehm U, et al.:Expert consensus document:European Consensus Statement on congenital hypogonadotropic hypogonadism--pathogenesis, diagnosis and treatment. Nat Rev Endocrinol 11:547-564, 2015.
PubMed
4) 日本小児泌尿器科学会学術委員会(編):停留精巣診療ガイドライン. 日小児泌会誌 14:117-152, 2005 https://jspu.jp/download/guideline/guideline_1.pdf
 
5) Sato N, et al.:Treatment situation of male hypogonadotropic hypogonadism in pediatrics and proposal of testosterone and gonadotropins replacement therapy protocols. Clin Pediatr Endocrinol 24:37-49, 2015
 
6) Dwyer AA, et al.:Trial of recombinant follicle-stimulating hormone pretreatment for GnRH-induced fertility in patients with congenital hypogonadotropic hypogonadism. J Clin Endocrinol Metab 98:E1790-E1795, 2013
PubMed
7) Sidhoum VF, et al.:Reversal and relapse of hypogonadotropic hypogonadism: resilience and fragility of the reproductive neuroendocrine system. J Clin Endocrinol Metab 99:861-870, 2014
PubMed
P.74 掲載の参考文献
1) 三善陽子:高ゴナドトロピン性性腺機能低下症. 日本小児内分泌学会(編), 小児内分泌学. 改訂第3版, 診断と治療社, 323-329, 2022
 
2) Rosenfield RL, et al.:Puberty in the female and its disorders:Hypogonadism. In:Sperling MA, et al.(eds), Sperling Pediatric Endocrinology. 5th ed, Elsevier, Philadelphia, 573-585, 2021
 
3) Palmert MR, et al.:Puberty and its disorders in the male:Delayed puberty. In:Sperling MA, et al.(eds), Sperling Pediatric Endocrinology, 5th ed, Elsevier, Philadelphia, 675-680, 2021
 
4) 日本小児内分泌学会(編):小児がん経験者(CCS)のための内分泌フォローアップガイド. 小児内分泌学会ガイドライン集. 中山書店, 278-321, 2018
 
5) 三善陽子, 他:性腺障害. 日本小児内分泌学会(編), 小児がん内分泌診療の手引き. 診断と治療社, 54-55, 2021
 
6) 日本小児内分泌学会(編):性分化疾患対応の手引き(小児期). 小児内分泌学会ガイドライン集. 中山書店, 72-77, 2018
 
7) 日本小児内分泌学会(編):ターナー症候群におけるエストロゲン補充療法ガイドライン. 小児内分泌学会ガイドライン集. 中山書店, 54-62, 2018
 
8) 日本女性医学学会(編):女性医学における治療法とその実際-薬物療法 1. ホルモン補充療法(HRT). 女性医学ガイドブック 更年期医療編 2019年度版. 金原出版, 351-373, 2019
 
9) 日本癌治療学会(編):小児. 小児, 思春期・若年がん患者の妊孕性温存に関する診療ガイドライン. 2017年版, 金原出版, 93-112, 2017
 

第5章 性分化・性発達異常を伴う疾患

P.76 掲載の参考文献
1) 日本小児科学会:小児科用語集第2版 https://www.jpeds.or.jp/uploads/files/yougo_2.pdf
 
2) Lee PA, et al.:Global Disorders of Sex Development Update since 2006:Perceptions, Approach and Care. Horm Res Paediatr 85:158-180, 2016
PubMed
3) Reiner WG, et al.:Discordant Sexual Identity in Some Genetic Males with Cloacal Exstrophy Assigned to Female Sex at Birth. N Engl J Med 350:333-341, 2004
 
4) Maimoun L, et al.:Phenotypical, biological, and molecular heterogeneity of 5α-reductase deficiency:an extensive international experience of 55 patients. J Clin Endocrinol Metab 96:296-307, 2011
 
5) Wallien MSC, et al.:Psychosexual Outcome of Gender-Dysphoric Children. J Am Acad Child Adolesc Psychiatry 47:1413-1423, 2008
 
6) Wagner S, et al.:Progression of Gender Dysphoria in Children and Adolescents:A Longitudinal Study. Pediatrics 148:e2020027722, 2021
PubMed
P.78 掲載の参考文献
1) Ishii T, et al.:A cross-sectional growth reference and chart of streched penile length for Japanese boys aged 0-7 years. Horm Res Pediatr 82:388-393, 2014
 
2) Ishii T, et al.:Testosterone enanthate therapy is effective and independent of SRD5A2 and AR gene polymorphisms in boys with micropenis. J Urol 172:319-324, 2004
PubMed
3) 佐々木悟郎, 他:ミクロペニスに対するテストステロン治療の効果. ホルモンと臨 49:1219-1223, 2001
 
4) Choi SK, et al.:Transdermal dihydrotestosterone therapy and its effects on patients with microphallus. J Urol 150:657-660, 1993
PubMed
5) Charmandari E, et al.:Kinetics and effect of percutaneous administration of dihydrotestosterone in children. Horm Res 56:177-181, 2001
PubMed
6) Sasaki G, et al.:Effects of pre- and post-pubertal dihydrotestosterone treatment on penile length in 5α-reductase type 2 deficiency. Endocr J 66:837-842, 2019
 
7) Becker D, et al.:Topical dihydrotestosterone to treat micropenis secondary to partial androgen insensitivity syndrome(PAIS) before, during, and after puberty-a case series. J Pediatr Endocrinol Metab 29:173-177, 2016
 
8) 国立成育医療研究センター薬剤部(編):小児の薬剤業務. 小児科領域の薬剤業務ハンドブック. 第2版, じほう, 39, 2016
 
9) Sato N, et al.:Treatment situation of male hypogonadotropic hypogonadism in pediatrics and proposal of testosterone and gonadotropins replacement therapy protocols. Clin Pediatr Endocrinol 24:37-49, 2015
 
10) Bhasin S, et al.:Testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 103:1715-1744, 2018
PubMed
11) Stancampiano MR, et al.:Testosterone therapy in adolescent boys:the need for a structured approach. Horm Res Pediatr 92:215-228, 2019
 
P.79 掲載の参考文献
1) Hiort O, et al.:Management of disorders of sex development. Nat Rev Endocrinol 10:520-529, 2014
PubMed
2) Wisniewski AB, et al.:Management of 46,XY Differences/Disorders of Sex Development (DSD) Throughout Life. Endocr Rev 40:1547-1572, 2019
PubMed
3) Mongan NP, et al.:Androgen insensitivity syndrome. Best Pract Res Clin Endocrinol Metab 29:569-580, 2015
PubMed
4) Klein KO, et al.:Estrogen Replacement in Turner Syndrome:Literature Review and Practical Considerations. J Clin Endocrinol Metab 103:1790-1803, 2018
PubMed
5) Amaral RC, et al.:Quality of life of patients with 46,XX and 46,XY disorders of sex development. Clin Endocrinol(Oxf) 82:159-164, 2015
PubMed
P.83 掲載の参考文献
1) Long CJ, et al.:Hypospadias. In:Partin AW, et al.(eds), Campbell-Walsh-Wein Urology. 12th ed, Elsevier, Philadelphia, 905-948, 2020
 
2) 吉野 薫:尿道下裂. 日本小児泌尿器科学会(編), 小児泌尿器科学. 診断と治療社, 190-192, 2021
 
3) 浅沼 宏:尿道下裂の手術 尿道板を温存する一期的修復. 山本新吾, 他(編), 小児泌尿器科手術. メジカルビュー社, 98-114, 2020
 
4) Palmer LS, et al.:Management of abnormalities of the external genitalia in boys. In:Partin AW, et al.(eds), Campbell-Walsh-Wein Urology. 12th ed, Elsevier, Philadelphia, 871-904, 2020
 
5) 西尾英紀:陰嚢自体の異常. 日本小児泌尿器科学会(編), 小児泌尿器科学. 診断と治療社, 228-229, 2021
 
6) 吉野 薫:尿道下裂の手術 尿道板を離断する一期的修復. 山本新吾, 他(編), 小児泌尿器科手術. メジカルビュー社, 115-128, 2020
 
7) 守屋仁彦:尿道下裂の手術 二期的修復. 山本新吾, 他(編), 小児泌尿器科手術. メジカルビュー社, 129-138, 2020
 
P.85 掲載の参考文献
1) Krege S, et al.:Variations of sex development: the first German interdisciplinary consensus paper. J Pediatr Urol 15:114-123, 2019
 
2) Speiser PW, et al.:Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency:An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 103:4043-4088, 2018
PubMed
3) Kaefer M, et al.:Treatment of the Enlarged Clitoris. Front Pediatr 5:125, 2017
PubMed
Speiser PW, et al.:Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 103:4043-4088, 2018
PubMed
P.88 掲載の参考文献
1) Gravholt CH, et al.:Clinical practice guidelines for the care of girls and women with Turner syndrome:proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur J Endocrinol 177:G1-G70, 2017
PubMed
2) Fechner PY, et al.: Differences in follicle-stimulating hormone secretion between 45,X monosomy Turner syndrome and 45,X/46,XX mosaicism are evident at an early age. J Clin Endocrinol Metab 91:4896-4902, 2006
 
3) 日本小児内分泌学会薬事委員会:ターナー症候群におけるエストロゲン補充療法ガイドライン. 日小児会誌 112:1048-1050, 2008
 
4) 日本産科婦人科学会, 他(編監):産婦人科診療ガイドライン-婦人科外来編 2020.日本産科婦人科学会事務局, 2020 http://www.jsog.or.jp/activity/pdf/gl_fujinka_2020.pdf
 
5) 小児慢性特定疾病情報センター:ターナー(Turner)症候群. https://www.shouman.jp/disease/details/05_41_088/
 
6) Frias JL, et al.:Health supervision for children with Turner syndrome. Pediatrics 111:692-702, 2003
PubMed
7) Schleedoorn MJ, et al.:International consensus:ovarian tissue cryopreservation in young Turner syndrome patients:outcomes of an ethical Delphi study including 55 experts from 16 different countries. Hum Reprod 35:1061-1072, 2020
PubMed
P.91 掲載の参考文献
1) Gravholt CH, et al.:Klinefelter syndrome:integrating genetics, neuropsychology, and endocrinology. Endocr Rev 39:389-423, 2018
PubMed
2) Groth KA, et al.:Clinical review:Klinefelter syndrome-a clinical update. J Clin Endocrinol Metab 98:20-30, 2013
PubMed
3) Corona G, et al.:Sperm recovery and ICSI outcomes in Klinefelter syndrome:a systematic review and meta-analysis. Hum Reprod Update 23:265-275, 2017
PubMed
4) Zitzmann M, et al.:European academy of andrology guidelines on Klinefelter Syndrome Endorsing Organization:European Society of Endocrinology. Andrology 9:145-167, 2021
 
P.93 掲載の参考文献
1) Practice Committee of American Society for Reproductive Medicine:Current evaluation of amenorrhea. Fertil Steril 90(5 Suppl.): S219-S225, 2008
 
2) 日本産科婦人科学会(編):産科婦人科用語集・用語解説集. 改訂第4版, 日本産科婦人科学会, 214, 2018
 
3) Gordon CM:Clinical practice. Functional hypothalamic amenorrhea. N Engl J Med 22:363:365-371, 2010
 
4) Sowinska-Przepiera E, et al.:Functional hypothalamic amenorrhoea-diagnostic challenges, monitoring, and treatment. Endokrynol Pol 66:252-260, 2015
PubMed
5) Sophie Gibson ME, et al.:Where Have the Periods Gone? The Evaluation and Management of Functional Hypothalamic Amenorrhea. J Clin Res Pediatr Endocrinol 12(Suppl. 1):18-27, 2020
 
6) 水沼英樹, 他:やせを伴う続発性無月経. 日本女性医学学会(編), 女性医学ガイドブック 思春期・性成熟期編2016年度版. 金原出版, 56-65, 2016
 
7) 水沼英樹, 他:女性アスリートへのヘルスケア. 日本女性医学学会(編), 女性医学ガイドブック思春期・性成熟期編2016年度版. 金原出版, 66-71, 2016
 
8) 水沼英樹, 他:月経関連疾患. 日本女性医学学会(編), 女性医学ガイドブック思春期・性成熟期編2016年度版. 金原出版, 80-119, 2016
 
9) Committee Opinion No.702:Female Athlete Triad. Obstet Gynecol 129:e160-e167, 2017
PubMed
10) Caronia LM, et al.:A genetic basis for functional hypothalamic amenorrhea. N Engl J Med 364:215-225, 2011
PubMed
11) La Marca A, et al.:Serum anti-mullerian hormone levels in women with secondary amenorrhea. Fertil Steril 85:1547-1549, 2006
PubMed
12) O'Donnell E, et al.:Clinical review:Cardiovascular consequences of ovarian disruption:a focus on functional hypothalamic amenorrhea in physically active women. J Clin Endocrinol Metab 96:3638-3648, 2011
PubMed
P.96 掲載の参考文献
1) Chen Z-J, et al.:Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromo-some 2p16.3, 2p21 and 9q33.3. Nat Genet 43:55-59, 2011
 
2) Shi Y, et al.:Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome. Nat Genet 44:1020-1025, 2012
PubMed
3) Witchel SF, et al.:Polycystic Ovary Syndrome: Pathophysiology, Presentation, and Treatment With Emphasis on Adolescent Girls. J Endocr Soc 3:1545-1573, 2019
PubMed
4) Witchel SF, et al.:The diagnosis of polycystic ovary syndrome during adolescence. Horm Res Paediatr 83:376-389, 2015
 
5) Brown M, et al.:Ovarian imaging by magnetic resonance in adolescent girls with polycystic ovary syndrome and age-matched controls. J Magn Reson Imaging 38:689-693, 2013
PubMed
6) Anderson AD, et al.:Childhood obesity and its impact on the development of adolescent PCOS. Semin Reprod Med 32:202-213, 2014
PubMed
7) Shaw N, et al:Treatment of polycystic ovarian syndrome in adolescents. UpToDate, Wolters Kluwer, Philadelphia, Last Update:Aug 25, 2020 http://www.uptodate.com/contents/treatment-of-polycystic-ovary-syndrome-in-adolescents
 
P.99 掲載の参考文献
1) 日本産婦人科学会, 他(編監):産婦人科診療ガイドライン-婦人科外来編 2020. 日本産婦人科学会事務局, XVIII-XXI, 2020
 
Munro MG, et al.:FIGO classification system (PALM-COEIN)for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet 113: 3-13, 2011
PubMed
Borzutzky C, et al.:Diagnosis and Management of Heavy Menstrual Bleeding and Bleeding Disorders in Adolescents.JAMA Pediatr 174:186-194, 2020
PubMed
Screening and Management of Bleeding Disorders in Adolescents With Heavy Menstrual Bleeding:ACOG COMMITTEE OPINION, Number 785. Obstet Gynecol 134:e71-e83, 2019
PubMed
日本産科婦人科学会, 他(編監):産婦人科診療ガイドライン-婦人科外来編2020. 日本産科婦人科学会事務局, 108-109, 2020
 
日本産科婦人科学会, 他(編監):OC・LEPガイドライン2020年度版. 日本産科婦人科学会・日本女性医学学会, 2021
 
日本産科婦人科学会(編):産科婦人科用語集・用語解説集. 改訂第4版, 日本産科婦人科学会, 2018
 
P.101 掲載の参考文献
1) 日本精神神経学会性同一性障害に関する委員会:性同一性障害に関する診断と治療のガイドライン(第4版改). https://www.jspn.or.jp/modules/advocacy/index.php?content_id=33
 
2) Hembree WC, et al.:Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons:An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 102:3869-3903, 2017
PubMed
3) 堀 友博:性別違和をもつ子どもへのホルモン療法(二次性徴抑制療法と成人へのトランジション). 小児科 63:21-29, 2022
 
4) 中塚幹也:性同一性障害(GID). 産科と婦人科 86(増刊号):190-195, 2019
 

第6章 副腎疾患

P.104 掲載の参考文献
1) Buonocore F, et al.:Primary adrenal insufficiency:New genetic causes and their long-term consequences. Clin Endocrinol (Oxf) 92:11-20, 2020
PubMed
2) Kirkgoz T, et al.:Primary adrenal insufficiency in children:Diagnosis and management. Best Pract Res Clin Endocrinol Metab 32:397-424, 2018
PubMed
3) Achermann J:Adrenal Glands--congenital adrenal hypoplasia. ICPED Consortium http://icped.org/revisions/0/2015/diagnoses/#!/8A.2a
 
4) 日本小児内分泌学会(性分化・副腎疾患委員会, マススクリーニング委員会), 他:21-水酸化酵素欠損症の診断・治療のガイドライン(2021年改訂版), 2021 http://jspe.umin.jp/medical/files/guide20211027.pdf
 
5) Yanase T, et al.:Diagnosis and treatment of adrenal insufficiency including adrenal crisis:a Japan Endocrine Society clinical practice guideline. Endocr J 63:765-784, 2016
PubMed
P.105 掲載の参考文献
1) Stewart PM, et al.:Glucocorticoid deficiency. In:Melmed S, et al.(eds), Williams Textbook of Endocrinology. 13th ed, Elsevier, Phiadelphia, 524-533, 2016
 
2) 日本内分泌学会, 他:副腎クリーゼを含む副腎皮質機能低下症の診断と治療に関する指針. 日内分泌会誌 91(Suppl.):1-78, 2015
 
P.107 掲載の参考文献
1) 明比祐子, 他:慢性副腎皮質機能低下症(原発性, 続発性).別冊日本臨牀 内分泌症候群 II-その他の内分泌疾患を含めて-. 第3版, 日本臨牀社, 9-13, 2018
 
2) Couture C, et al.:Phenotypic homogeneity and genotypic variability in a large series of congenital isolated ACTH-deficiency patients with TPIT gene mutations. J Clin Endocrinol Metab 97:E486-495, 2012
 
3) Farooqi IS, et al.:Heterozygosity for a POMC-null mutation and increased obesity risk in humans. Diabetes 55:2549-2553, 2006
PubMed
4) 柳瀬敏彦, 他:副腎クリーゼを含む副腎皮質機能低下症の診断と治療に関する指針. 日内分泌会誌 91(Suppl.):1-78, 2015
 
5) 日本小児内分泌学会(編):小児がん内分泌疾患診療の手引き. 診断と治療社, 2021
 
6) Maharaj A, et al.:Isolated glucocorticoid deficiency:Genetic causes and animal models. J Steroid Biochem Mol Biol 189:73-80, 2019
PubMed
7) Meimaridou E, et al.:Familial glucocorticoid deficiency:New genes and mechanisms. Mol Cell Endocrinol 371:195-200, 2013
PubMed
8) Clark AJ, et al.:Familial glucocorticoid deficiency associated with point mutation in the adrenocorticotropin receptor. Lancet 341:461-462, 1993
PubMed
9) Metherell LA, et al.:Mutations in MRAP, encoding a new interacting partner of the ACTH receptor, cause familial glucocorticoid deficiency type 2. Nat Genet 37:166-170, 2005
PubMed
10) Meimaridou E, et al.:Mutations in NNT encoding nicotinamide nucleotide transhydrogenase cause familial glucocorticoid deficiency. Nat Genet 44:740-742, 2012
PubMed
11) Prasad R, et al.:Thioredoxin Reductase 2 (TXNRD2)mutation associated with familial glucocorticoid deficiency(FGD). J Clin Endocrinol Metab 99:E1556-1563, 2014
PubMed
12) Tullio-Pelet A, et al.:Mutant WD-repeat protein in triple-A syndrome. Nat Genet 26:332-335, 2000
PubMed
13) Patt H, et al.:Phenotype-genotype spectrum of AAA syndrome from Western India and systematic review of literature. Endocr Connect 6:901-913, 2017
PubMed
14) Ikeda M, et al.:Triple A syndrome in Japan. Muscle Nerve 48:381-386, 2013
PubMed
P.108 掲載の参考文献
1) Moser HW, et al.:X-linked adrenoleukodystrophy. Nat Clin Pract Neurol 3:140-151, 2007
PubMed
2) Shimozawa N, et al.:X-linked adrenoleukodystrophy:diagnostic and follow-up system in Japan. J Hum Genet 56:106-109, 2011
PubMed
3) 日本先天代謝異常学会(編):副腎白質ジストロフィー(ALD)診療ガイドライン2019. 診断と治療社, 2019
 
4) 副腎白質ジストロフィー診療ハンドブック2013作成委員会(編), 下澤伸行(監修):副腎白質ジストロフィー診療ハンドブック2013:ALD患者を支えている関係者の皆様へ. 2013
 
5) Huffnagel IC, et al.:The Natural History of Adrenal Insufficiency in X-Linked Adrenoleukodystrophy:An International Collaboration. J Clin Endocrinol Metab 104:118-126, 2019
 
6) Zhu J, et al.:The Changing Face of Adrenoleukodystrophy. Endocr Rev 41:577-593, 2020
PubMed
7) 日本内分泌学会, 他:副腎クリーゼを含む副腎皮質機能低下症の診断と治療に関する指針. 日内分泌会誌 91(Suppl):1-78, 2015
 
8) Bornstein SR, et al.:Diagnosis and Treatment of Primary Adrenal Insufficiency:An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 101:364-389, 2016
PubMed
P.110 掲載の参考文献
1) 小児慢性特定疾病情報センター:アルドステロン合成酵素欠損症-診断の手引き. https://www.shouman.jp/disease/instructions/05_23_047/
 
2) Arai K, et al.:Aldosterone Deficiency and Resistance. In:Feingold KR, et al.(eds), Endotext[Internet] MDText.com, Inc., South Dartmouth (MA), Last Update:Nov 24, 2020
 
P.111 掲載の参考文献
1) Ishii T, et al.:Incidence and Characteristics of Adrenal Crisis in Children Younger than 7 Years with 21-Hydroxylase Deficiency:A Nationwide Survey in Japan. Horm Res Paediatr 89:166-171, 2018
PubMed
2) Newell-Price JDC, et al.:The Adrenal Cortex. In:Melmed S, et al.(eds), Williams Textbook of Endocrinology. 14th ed, Elsevier, Philadelphia, 480-541, 2020
 
3) Nanao K, et al.:Morning hypoglycemia leading to death in a child with congenital hypopituitarism. Acta Paediatr 88:1173, 1999
 
4) Rushworth RL, et al.:Adrenal Crises in Children:Perspectives and Research Directions. Horm Res Paediatr 89:341-351, 2018
PubMed
5) Aso K, et al.:Stress doses of glucocorticoids cannot prevent progression of all adrenal crises. Clin Pediatr Endocrinol 18:23-27, 2009
PubMed
6) 長谷川行洋:副腎皮質疾患-副腎不全. たのしく学ぶ小児内分泌. 診断と治療社, 268-276, 2015
 
7) Bornstein SR, et al.:Diagnosis and Treatment of Primary Adrenal Insufficiency:An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 101:364-389, 2016
PubMed
8) Coursin DB, et al.:Corticosteroid supplementation for adrenal insufficiency. JAMA 287:236-240, 2002
PubMed
9) Prete A, et al.:Prevention of Adrenal Crisis:Cortisol Responses to Major Stress Compared to Stress Dose Hydrocortisone Delivery. J Clin Endoctinol Metab 105:2262-2274, 2020
 
10) Ishii T, et al.:Guidelines for diagnosis and treatment of 21-hydroylase deficiency (2014 revision). Clin Pediatr Endocrinol 24:77-105, 2015
 
P.113 掲載の参考文献
1) 内木康博:慢性・急性副腎皮質機能低下症. 小児内科 49:250-255, 2017
Medical*Online
2) Goto M, et al.:High incidence of adrenal suppression in children with Kawasaki disease treated with intravenous immunoglobulin plus prednisolone. Endocr J 62:145-51, 2015
PubMed
3) 日本小児内分泌学会(編):小児がん内分泌診療の手引き. 診断と治療社, 2021
 
4) 柳瀬敏彦, 他:副腎クリーゼを含む副腎皮質機能低下症の診断と治療に関する指針. 日内分泌会誌 91(Suppl.):1-78, 2015
 
5) Kazlauskaite R, et al.:Pitfalls in the diagnosis of central adrenal insufficiency in children. Endocr Dev 17:96-107, 2010
PubMed
6) Goto M, et al.:Efficacy of single serum cortisol reading obtained between 9 AM and 10 AM as an index of adrenal function in children treated with glucocorticoids or synthetic adrenocorticotropic hormone. Clin Pediatr Endocrinol 25:83-89, 2016
PubMed
P.115 掲載の参考文献
1) Aguilera G:Regulation of pituitary ACTH secretion during chronic stress. Front Neuroendocrinol 15:321-350, 1994
PubMed
2) Axelrod L:Glucocorticoid therapy. Medicine (Baltimore) 55:39-65, 1976
PubMed
3) Westerhof L, et al.:Recovery of adrenocortical function during long-term treatment with corticosteroids. Br Med J 4:534-537, 1970
PubMed
4) Zaghiyan K, et al. Are high-dose perioperative steroids necessary in patients undergoing colorectal surgery treated with steroid therapy within the past 12 months? Am Surg 77:1295-1299, 2011
PubMed
5) Todd GRG, et al.:Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child 87:457-461, 2002
PubMed
6) Hagg E, et al.:Value of basal plasma cortisol assays in the assessment of pituitary-adrenal insufficiency. Clin Endocrinol (Oxf) 26:221-226, 1987
PubMed
7) Deutschbein T, et al.:Diagnosis of secondary adrenal insufficiency:unstimulated early morning cortisol in saliva and serum in comparison with the insulin tolerance test. Horm Metab Res 41:834-839, 2009
PubMed
8) 堀川玲子, 他:慢性副腎不全患者の手術等. 横谷 進, 他(編), 専門医による新小児内分泌疾患の治療. 改訂第2版, 診断と治療社, 125, 2017
 
9) 日本小児内分泌学会(編):小児がん内分泌診療の手引き. 診断と治療社, 2021
 
10) Salem M, et al.:Perioperative glucocorticoid coverage. A reassessment 42 years after emergence of a problem. Ann Surg 219:416-425, 1994
PubMed
11) 堀川玲子, 他:慢性副腎不全患者の手術等. 横谷 進, 他(編), 専門医による新小児内分泌疾患の治療. 改訂第2版, 診断と治療社, 126, 2017
 
12) Yong SL, et al.:Supplemental perioperative steroids for surgical patients with adrenal insufficiency. Cochrane Database Syst Rev Oct 7:CD005367, 2009
 
P.117 掲載の参考文献
1) Kawai M:Late onset circulatory collapse of prematurity. Pediatr Int 59:391-396, 2017
PubMed
2) Kawai M, et al.:Nationwide surveillance of circulatory collapse associated with levothyroxine administration in very-low-birth-weight infants in Japan. Pediatr Int 54:177-181, 2012
PubMed
3) Marinelli KC, et al.:Clinical risk factors for the development of late-onset circulatory collapse in premature infants. Pediatr Res 89:968-973, 2021
PubMed
4) Masumoto K, et al.:Comparison of serum cortisol concentrations in preterm infants with or without late-onset circulatory collapse due to adrenal insufficiency of prematurity. Pediatr Res 63:686-690, 2008
PubMed
5) Iwanaga K, et al.:Corticotrophin-releasing hormone stimulation tests for the infants with relative adrenal insufficiency. Clin Endocrinol (Oxf) 87:660-664, 2017
PubMed
6) Washio Y, et al.:Hemodynamic analysis in infants with late-onset circulatory collapse. Pediatr Int 55:582-588, 2013
PubMed
7) Nakanishi H, et al.:Clinical characterization and long-term prognosis of neurological development in preterm infants with late-onset circulatory collapse. J Perinatol 30:751-756, 2010
PubMed
P.123 掲載の参考文献
1) 日本小児内分泌学会(性分化・副腎疾患委員会, マススクリーニング委員会), 他:21- 水酸化酵素欠損症の診断・治療のガイドライン(2021年改訂版), 2021 http://jspe.umin.jp/medical/files/guide20211027.pdf
 
2) Gau M, et al.:The progression of salt-wasting and the body weight change during the first 2 weeks of life in classical 21-hydroxylase deficiency patients. Clin Endocrinol 94:229-236, 2021
PubMed
3) Koyama Y, et al.:Two-step biochemical differential diagnosis of classic 21-hydroxylase deficiency and cytochrome P450 oxidoreductase deficiency in Japanese infants by GC-MS measurement of urinary pregnanetriolone/tetrahydroxycortisone ratio in 11β-hydroxyandrosterone. Clin Chem 58:741-747, 2012
 
4) Merke DP, et al.:Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency. N Engl J Med 383:1248-1261, 2020
PubMed
5) Izawa M, et al.:Pregnanetriol in the Range of 1.2-2.1mg/m(2)/day as an Index of Optimal Control in CYP21A2 Deficiency. Clin Pediatr Endocrinol 16:45-52, 2007
Medical*Online
6) Muthusamy K, et al.:Clinical review:Adult height in patients with congenital adrenal hyperplasia:a systematic review and metaanalysis. J Clin Endocrinol Metab 95:4161-4172, 2010
PubMed
7) Tamhane S, et al.:Cardiovascular and Metabolic Outcomes in Congenital Adrenal Hyperplasia:A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab 103:4097-4103, 2018
PubMed
P.125 掲載の参考文献
1) Stocco DM, et al.:Regulation of the acute production of steroids in steroidogenic cells. Endocr Rev 17:221-244, 1996
PubMed
2) Baquedano MS, et al.:Unique dominant negative mutation in the N-terminal mitochondrial targeting sequence of StAR, causing a variant form of congenital lipoid adrenal hyperplasia. J Clin Endocrinol Metab 98:E153-E161, 2013
 
3) Ishii T, et al.:Pubertal and Adult Testicular Functions in Nonclassic Lipoid Congenital Adrenal Hyperplasia:A Case Series and Review. J Endocr Soc 3:1367-1374, 2019
PubMed
4) Ishii T, et al.:Gonadal macrophage infiltration in congenital lipoid adrenal hyperplasia. Eur J Endocrinol 175:127-132, 2016
PubMed
5) Ishii T, et al.:Clinical Features of 57 Patients with Lipoid Congenital Adrenal Hyperplasia:Criteria for Nonclassic Form Revisited. J Clin Endocrinol Metab 105:e3929-e3937, 2020
 
P.127 掲載の参考文献
1) 田辺晶代, 他:17α-水酸化酵素欠損症. 日本臨牀 63(増刊 3):292-295, 2005
 
2) 田島敏広:17α-水酸化酵素欠損症(17α-OHD). 横谷進, 他(編), 専門医による新小児内分泌疾患の治療. 改訂第2版, 診断と治療社, 138-140, 2017
 
3) 藤枝憲二:先天性副腎過形成(11β-OHと17-αOH欠損症).血圧 7:39-45, 2000
 
4) Martin RM, et al.:P450c17 deficiency in Brazilian patients:biochemical diagnosis through progesterone levels confirmed by CYP17 genotyping. J Clin Endocrinol Metab 88:5739-5746, 2003
PubMed
5) RJ Auchus:The genetics, pathophysiology, and management of human deficiencies of P450c17. Endocrinol Metab Clin North Am 30:101-119, vii, 2001
 
6) Kater CE, et al.:The unique patterns of plasma aldosterone and 18-hydroxycorticosterone concentrations in the 17 alpha-hydroxylase deficiency syndrome. J Clin Endocrinol Metab 55:295-302, 1982
 
7) Bianchi PH, et al.:Successful Live Birth in a Woman With 17α-Hydroxylase Deficiency Through IVF Frozen-Thawed Embryo Transfer. J Clin Endocrinol Metab 101:345-348, 2016
 
P.129 掲載の参考文献
1) 田島敏広:11β-水酸化酵素欠損症. 横谷 進, 他(編), 専門医による新小児内分泌疾患の治療. 改訂第2版, 診断と治療社, 141-143, 2017
 
2) 渡邉早苗, 他:11β-水酸化酵素欠損症. 日本臨牀 63(増刊 3):288-291, 2005
 
3) Bulsar K, et al.:Clinical perspectives in congenital adrenal hyperplasia due to 11β-hydroxylase deficiency. Endocrine 55:19-36, 2017
 
4) Azziz R, et al.:11 beta hydroxylase deficiency in hyperandrogenism. Fertil Steril 55:733-741, 1991
 
5) Falhammar H, et al.:Clinical outcomes in the management of congenital adrenal hyperplasia. Endocrine 41:355-373, 2012
PubMed
P.132 掲載の参考文献
1) Simard J, et al.:Molecular biology of the 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family. Endocr Rev 26:525-582, 2005
PubMed
2) Miller WL, et al.:The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev 32:81-151, 2011
PubMed
3) 副腎ホルモン産出異常に関する調査研究班:3β-水酸化ステロイド脱水素酵素欠損症診断の手引き. 副腎ホルモン産出異常に関する調査研究. http://www.pediatric-world.com/fukujin/p10.html
 
4) Guran T, et al.:Revisiting Classical 3β-hydroxysteroid Dehydrogenase 2 Deficiency:Lessons from 31 Pediatric Cases. J Clin Endocrinol Metab 105:dgaa022, 2020
 
5) Lutfallah C, et al.:Newly proposed hormonal criteria via genotypic proof for type II 3beta-hydroxysteroid dehydrogenase deficiency. J Clin Endocrinol Metab 87:2611-2622, 2002
PubMed
6) Mermejo LM, et al.:Refining hormonal diagnosis of type II 3beta-hydroxysteroid dehydrogenase deficiency in patients with premature pubarche and hirsutism based on HSD3B2 genotyping. J Clin Endocrinol Metab 90:1287-1293, 2005
PubMed
7) Baronio F, et al.:46,XX DSD due to Androgen Excess in Monogenic Disorders of Steroidogenesis:Genetic, Biochemical, and Clinical Features. Int J Mol Sci 20:4605, 2019
PubMed
8) Al Alawi AM, et al.:Clinical perspectives in congenital adrenal hyperplasia due to 3β-hydroxysteroid dehydrogenase type 2 deficiency. Endocrine 63:407-421, 2019
 
9) Benkert AR, et al.:Severe Salt-Losing 3β-Hydroxysteroid Dehydrogenase Deficiency:Treatment and Outcomes of HSD3B2 c.35G>A Homozygotes. J Clin Endocrinol Metab 100:E1105-1115, 2015
 
P.135 掲載の参考文献
1) Yatsuga S, et al.:Clinical characteristics of cytochrome P450 oxidoreductase deficiency:a nationwide survey in Japan.Endocr J 67:853-857, 2020
PubMed
2) Unal E, et al.:Cytochrome P450 oxidoreductase deficiency caused by a novel mutation in the POR gene in two siblings:case report and literature review. Hormones (Athens) 20:293-298, 2021
PubMed
3) 深見真紀, 他:チトクロームP450オキシドレダクターゼ(POR)異常症の分子基盤:POR遺伝子発現制御機構. 日生殖内分泌会誌 17:17-20, 2012
 
4) Idkowiak J, et al.:Cytochrome P450 Oxidoreductase Deficiency. In:Adam MP, et al.(eds), GeneReviews[Internet]. University of Washington, Seattle, Last Update:Aug 3, 2017
 
5) 日本小児内分泌学会(性分化・副腎疾患委員会, マススクリーニング委員会), 他:21-水酸化酵素欠損症の診断・治療のガイドライン(2021年改訂版), 2021 http://jspe.umin.jp/medical/files/guide20211027.pdf
 
6) Fukami M, et al.:Cytochrome P450 oxidoreductase deficiency:identification and characterization of biallelic mutations and genotype-phenotype correlations in 35 Japanese patients. J Clin Endocrinol Metab 94:1723-1731, 2009
PubMed
7) Idkowiak J, et al.:Pubertal presentation in seven patients with congenital adrenal hyperplasia due to P450 oxidoreductase deficiency. J Clin Endocrinol Metab 96:E453-462, 2011
PubMed
P.137 掲載の参考文献
1) Jaaskelainen J, et al.:Sexual function and fertility in adult females and males with congenital adrenal hyperplasia. Horm Res 56:73-80, 2001
PubMed
2) Meyer-Bahlburg HF:What causes low rates of child-bearing in congenital adrenal hyperplasia? J Clin Endocrinol Metab 84:1844-1847, 1999
PubMed
3) Auchus RJ, et al.:Approach to the patient:the adult with congenital adrenal hyperplasia. J Clin Endocrinol Metab 98:2645-2655, 2013
 
4) Holmes-Walker DJ, et al.:Menstrual disturbance and hypersecretion of progesterone in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clin Endocrinol (Oxf) 43:291-296, 1995
PubMed
5) King TF, et al.:Experience in optimizing fertility outcomes in men with congenital adrenal hyperplasia due to 21 hydroxylase deficiency. Clin Endocrinol (Oxf) 84:830-836, 2016
PubMed
6) Speiser PW, et al.:Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency:An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 103:4043-4088, 2018
PubMed
7) Lo JC, et al.:Normal female infants born of mothers with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 84:930-936, 1999
PubMed
8) Lindsay JR, et al.:The hypothalamic-pituitary-adrenal axis in pregnancy:challenges in disease detection and treatment. Endocr Rev 26:775-799, 2005
PubMed
9) Bonaccorsi AC, et al.:Male infertility due to congenital adrenal hyperplasia:testicular biopsy findings, hormonal evaluation, and therapeutic results in three patients. Fertil Steril 47:664-670, 1987
PubMed
10) Marchini GS, et al.:Testicular adrenal rest tumor in infertile man with congenital adrenal hyperplasia:case report and literature review. Sao Paulo Med J 129:346-351, 2011
PubMed
11) Albarel F, et al.:Successful IVF pregnancy despite inadequate ovarian steroidogenesis due to congenital lipoid adrenal hyperplasia (CLAH):a case report. Hum Reprod 31:2609-2612, 2016
PubMed
P.138 掲載の参考文献
1) New MI, et al.:Prenatal diagnosis for congenital adrenal hyperplasia in 532 pregnancies. J Clin Endocrinol Metab 86:5651-5657, 2001
PubMed
2) Tardy-Guidollet V, et al.:New management strategy of pregnancies at risk of congenital adrenal hyperplasia using fetal sex determination in maternal serum:French cohort of 258 cases (2002-2011). J Clin Endocrinol Metab 99:1180-1188, 2014
PubMed
3) Merce Fernandez-Balsells M, et al.:Prenatal dexamethasone use for the prevention of virilization in pregnancies at risk for classical congenital adrenal hyperplasia due to 21 hydroxylase (CYP21A2) deficiency:a systematic review and meta-analyses. Clin Endocrinol (Oxf) 73:436-444, 2010
PubMed
4) Joint LWPES/ESPE CAH Working Group:Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. J Clin Endocrinol Metab 87:4048-4053, 2002
 
5) Miller WL:Genetics, diagnosis, and management of 21-hydroxylase deficiency. J Clin Endocrinol Metab 78:241-246, 1994
 
6) Dorr HG, et al.:Experts' Opinion on the Prenatal Therapy of Congenital Adrenal Hyperplasia (CAH) Due to 21-Hydroxylase Deficiency-Guideline of DGKED in cooperation with DGGG (S1-Level, AWMF Registry No.174/013, July 2015). Geburtshilfe Frauenheilkd 75:1232-1238, 2015
PubMed
7) Bachelot A, et al.:MANAGEMENT OF ENDOCRINE DISEASE:Congenital adrenal hyperplasia due to 21-hydroxylase deficiency:update on the management of adult patients and prenatal treatment. Eur J Endocrinol 176:R167-R181, 2017
PubMed
8) Speiser PW, et al.:Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency:an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 103:4043-4088, 2018
PubMed
9) 日本小児内分泌学会(性分化・副腎疾患委員会, マススクリーニング委員会), 他:21-水酸化酵素欠損症の診断・治療のガイドライン(2021年改訂版), 2021 http://jspe.umin.jp/medical/files/guide20211027.pdf
 
P.141 掲載の参考文献
1) 小児慢性特定疾病情報センター:クッシング(Cushing)病-診断の手引き https://www.shouman.jp/disease/instructions/05_18_033/
 
2) Nieman LK :Medical therapy of hypercortisolism (Cushing's syndrome). In:UpToDate, Wolters Kluwer, Philadelphia, Last Update:Apr 6, 2021 https://www.uptodate.com/contents/medical-therapy-of-hypercortisolism-cushings-syndrome
 
3) Ritchey AK et al.(eds):Childhood Adrenocortical Carcinoma Treatment (PDQ)-Health Processional Version. National Cancer Institute, Last Update:September 17, 2021 https://www.cancer.gov/types/adrenocortical/hp/child-adrenocortical-treatment-pdq#cit/section_7.3
 
4) Tanaka T, et al.:A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11β-hydroxylase inhibitor, in Japanese patients with endogenous Cushing's syndrome other than Cushing's disease. Endocri J 67:841-852, 2020
 
5) 日本内分泌学会, 他:副腎クリーゼを含む副腎皮質機能低下症の診断と治療に関する指針. 日内分泌会誌 91(Suppl.):1-78, 2015
 
P.144 掲載の参考文献
1) Sutherland DJ, et al.:Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can Med Assoc J 95:1109-1119, 1966
PubMed
2) 林 美恵, 他:グルココルチコイド反応性アルドステロン症(GRA). ホルモンと臨 60:189-192, 2012
 
3) Funder JW, et al.:The Management of Primary Aldosteronism:Case Detection, Diagnosis, and Treatment:An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 101:1889-1916, 2016
PubMed
4) Aglony M, et al.:Frequency of familial hyperaldosteronism type 1 in a hypertensive pediatric population:clinical and biochemical presentation. Hypertension 57:1117-1121, 2011
 
5) Litchfield WR, et al.:Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism. Hypertension 31:445-450, 1998
PubMed
P.145 掲載の参考文献
1) Carvajal CA, et al.:Classic and Nonclassic Apparent Mineralocorticoid Excess Syndrome. J Clin Endocrinol Metab 105:dgz315, 2020
PubMed
2) 宗 友厚:11βHSDタイプ2欠損症(AME症候群). 別冊日本臨牀 内分泌症候群II-その他の内分泌疾患を含めて-. 第3版, 日本臨牀社, 131-135, 2018
 
3) Funder JW:Apparent mineralocorticoid excess. J Steroid Biochem Mol Biol 165:151-153, 2017
PubMed
P.148 掲載の参考文献
1) 日本内分泌学会(監):褐色細胞腫・バラガングリオーマ診療ガイドライン2018. 診断と治療社, 2018
 
2) 田辺晶代, 他:褐色細胞腫・パラガングリオーマ(PPGL)診療の進歩. 日本臨牀 78(増刊号 2):335-340, 2020
 
3) 松原史明, 他:小児von Hippel-Lindau病の両側褐色細胞腫に対するα-メチルパラタイロシンの使用経験. 日内分泌会誌 94:318, 2018
Medical*Online
4) 立木美香, 他:副腎腫瘍の治療(5)薬物治療 3)褐色細胞腫. 日本臨牀 78(増刊号 4):675-678, 2020
 
5) Favier J, et al.:Paraganglioma and phaeochromocytoma:from genetics to personalized medicine. Nat Rev Endocrinol 11:101-111, 2015
PubMed
6) Amar L, et al.:International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. Nat Rev Endocrinol 17:435-444, 2021
PubMed

第7章 甲状腺疾患

P.151 掲載の参考文献
1) 日本小児内分泌学会マススクーリング委員会, 他:先天性甲状腺機能低下症マススクリーニングガイドライン(2021年改訂版). 2021 http://jspe.umin.jp/medical/files/guide20211027_2.pdf
 
2) Alexander EK, et al:Timing and magnitude of increases in levothyroxine requirements during pregnancy in women with hypothyroidism. N Engl J Med 351:241-249, 2004
PubMed
P.154 掲載の参考文献
1) 日本小児内分泌学会マススクリーニング委員会, 他:先天性甲状腺機能低下症マススクリーニングガイドライン(2021年改訂版).2021 http://jspe.umin.jp/medical/files/guide20211027_2.pdf
 
2) Rastogi MV, et al.:Congenital hypothyroidism. Orphanet J Rare Dis 5:17, 2010
PubMed
3) Nishiyama S, et al.:Transient hypothyroidism or persistent hyperthyrotropinemia in neonates born to mothers with excessive iodine intake. Thyroid 14:1077-1083, 2004
PubMed
4) Matsuura N, et al.:Familial neonatal transient hypothyroidism due to maternal TSH-binding inhibitor immunoglobulins. N Engl J Med 303:738-741, 1980
PubMed
5) Cheron RG, et al.:Neonatal thyroid function after propylthiouracil therapy for maternal Graves' disease. N Engl J Med 304:525-528, 1981
PubMed
6) Moreno JC, et al.:Inactivating mutations in the gene for thyroid oxidase 2 (THOX2) and congenital hypothyroidism. N Engl J Med 347:95-102, 2002
PubMed
7) Maruo Y, et al.:Transient congenital hypothyroidism caused by biallelic mutations of the dual oxidase 2 gene in Japanese patients detected by a neonatal screening program. J Clin Endocrinol Metab 93:4261-4267, 2008
 
8) Soulioti AM, et al.:Transient neonatal hypothyroidism in very low birthweight infants:is treatment necessary? Lancet 2:493-494, 1985
PubMed
9) 日本甲状腺学会(編):バセドウ病治療ガイドライン2019. 南江堂, 2019
 
10) Polak M, et al.:Therapeutic approach of fetal thyroid disorders. Horm Res Paediatr 74:1-5, 2010
PubMed
11) Ribault V, et al.:Experience with intraamniotic thyroxine treatment in nonimmune fetal goitrous hypothyroidism in 12 cases. J Clin Endocrinol Metab 94:3731-3739, 2009
 
P.156 掲載の参考文献
1) 山田正信, 他:中枢性甲状腺機能低下症. 日内会誌 99:720-725, 2010
 
2) Garcia M, et al.:Central hypothyroidism in children. Endocr Dev 26:79-107, 2014
PubMed
3) Persani L:Central hypothyroidism:pathogenic, diagnostic, and therapeutic challenges. J Clin Endocrinol Metab 97:3068-3078, 2012
PubMed
4) Beck-Peccoz P, et al.:Central hypothyroidism-a neglected thyroid disorder. Nat Rev Endocrinol 13:588-598, 2017
PubMed
P.157 掲載の参考文献
1) Nagayama Y:Radiation-related thyroid autoimmunity and dysfunction. J Radiat Res 59(Suppl. 2):ii98-ii107, 2018
 
2) 日本甲状腺学会:慢性甲状腺炎(橋本病)の診断ガイドライン. 甲状腺疾患診断ガイドライン 2021(2021年6月7日改定) http://www.japanthyroid.jp/doctor/guideline/japanese.html#mansei
 
3) 小児慢性特定疾病情報センター:内分泌疾患の疾患一覧 https://www.shouman.jp/disease/search/group/list/05/内分泌疾患
 
4) Admoni O, et al.:Long-Term Follow-Up and Outcomes of Autoimmune Thyroiditis in Childhood. Front Endocrinol(Lausanne) 11:309, 2020
PubMed
5) Hanley P, et al.:Thyroid Disorders in Children and Adolescents:A Review. JAMA Pediatr 170:1008-1019, 2016
PubMed
6) 南谷幹史, 他:5年後に甲状腺機能亢進症に進展した, 成長障害, 粘液水腫を伴った橋本病の一女児例. ホルモンと臨 56(Suppl.):88-93, 2008
 
7) Resende de Paiva C, et al.:Association between Hashimoto's Thyroiditis and Thyroid Cancer in 64, 628 Patients. Front Oncol 7:53, 2017
 
8) Sur ML, et al.:Papillary thyroid carcinoma in children with Hashimoto's thyroiditis-a review of the literature between 2000 and 2020. J Pediatr Endocrinol Metab 33:1511-1517, 2020
PubMed
P.159 掲載の参考文献
1) 日本甲状腺学会甲状腺粘液水腫性昏睡の診断基準と治療指針の作成委員会:粘液水腫性昏睡診断基準第3次案(2010年12月) http://www.japanthyroid.jp/doctor/img/shindan.pdf
 
2) Ono Y, et al.:Clinical characteristics and outcomes of myxedema coma:Analysis of a national inpatient database in Japan. J Epidemiol 27:117-122, 2017
PubMed
3) De Sanctis V, et al.:The Myxedema coma in children and adolescents:A rare endocrine emergency-Personal experience and review of literature. Acta Biomed 92:e2021481, 2021
PubMed
4) 田中祐司, 他:粘液水腫性昏睡の診断基準と治療方針. 日甲状腺会誌 4:47-52, 2013
 
5) Burman KD, et al.:Myxedema coma. In:Cooper DS, et al. (eds), Werner & Ingbar's the Thyroid:A fundamental and clinical text. 11th ed, Wolters Kluwer. Philadelphia. 605-611, 2021
 
P.167 掲載の参考文献
1) 日本甲状腺学会:バセドウ病の診断ガイドライン. 甲状腺疾患診断ガイドライン2021(2021年6月7日改定) http://www.japanthyroid.jp/doctor/guideline/japanese.html
 
2) 日本小児内分泌学会, 他:小児期発症バセドウ病診療のガイドライン2016. 2016 http://jspe.umin.jp/medical/files/gravesdisease_guideline2016.pdf
 
3) 日本甲状腺学会:バセドウ病治療ガイドライン2019. 南江堂, 2019
 
4) Nakamura H, et al.:Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab 92:2157-2162, 2007
PubMed
5) Sato S, et al.:Comparison of efficacy and adverse effects between methimazole 15 mg+inorganic iodine 38 mg/day and methimazole 30 mg/day as initial therapy for Graves' disease patients with moderate to severe hyperthyroidism. Thyroid25:43-50, 2015
 
6) Konishi T, et al.:Drug discontinuation after treatment with minimum maintenance dose of an antithyroid drug in Graves' disease:a retrospective study on effects of treatment duration with minimum maintenance dose on lasting remission. Endocr J 58:95-100, 2011
PubMed
7) Leger J, et al.:Positive impact of long-term antithyroid drug treatment on the outcome of children with Graves's disease:national long-term cohort study. J Clin Endocrinol Metab 97:110-119, 2012
 
8) Wang MT, et al.:Antithyroid drug-related hepatotoxicity in hyperthyroidism patients:a population-based cohort study. Br J Clin Pharmacol 78:619-629, 2014
PubMed
9) Pecere A, et al:Methimazole Treatment and Risk of Acute Pancreatitis:A Population-based Cohort Study. J Clin Endocrinol Metab 105:dgaa544, 2020
PubMed
10) Isozaki O, et al.:Treatment and management of thyroid storm:analysis of the nationwide surveys:The taskforce committee of the Japan Thyroid Association and Japan Endocrine Society for the establishment of diagnostic criteria and nationwide surveys for thyroid storm. Clin Endocrinol(Oxf) 84:912-918, 2016
PubMed
11) Okumura K, et al. Remission after potassium iodide therapy in patients with Graves' hyperthyroidism exhibiting thionamide-associated side effects. J Clin Endocrinol Metab 99:3995-4002, 2014
 
12) Cole M, et al.:Adjuvant rituximab, a potential treatment for the young patient with Graves' hyperthyroidism (RiGD):study protocol for a single-arm, single-stage, phase II trial. BMJ Open 9:e024705, 2019
 
13) Sugino K, et al.:Change of surgical strategy for Graves' disease from subtotal thyroidectomy to total thyroidectomy:a single institutional experience. Endocr J 66:181-186, 2019
PubMed
P.169 掲載の参考文献
1) 日本甲状腺学会, 他(編):甲状腺クリーゼの診断基準(第2版), 2010 http://www.japanthyroid.jp/doctor/img/crisis2.pdf
 
2) Akamizu T, et al.:Diagnostic criteria, clinical features, and incidence of thyroid storm based on nationwide surveys. Thyroid 22:661-679, 2012
PubMed
3) 日本甲状腺学会, 他(編):甲状腺クリーゼ診療ガイドライン2017. 南江堂. 2017 https://minds.jcqhc.or.jp/n/med/4/med0345/G0001030
 
4) Satoh T, et al.:2016 Guideline for the management of thyroid storm from the Japan Thyroid Association and Japan Endocrine Society (First edition). Endocr J 63:1025-1064, 2016
PubMed
5) Isozaki O, et al. Treatment and management of thyroid storm:analysis of the nationwide surveys. Clin Endocrinol (Oxf) 84:912-918, 2016
PubMed
6) Lazar L, et al.:Thyrotoxicosis in prepubertal children compared with pubertal and postpubertal patients. J Clin Endocrinol Metab 85:3678-3682, 2000
PubMed
P.171 掲載の参考文献
1) Nishihara E, et al.:Prevalence of TSH receptor and Gsalpha mutations in 45 autonomously functioning thyroid nodules in Japan. Endocr J 56:791-798, 2009
PubMed
2) 溝上哲也:機能性結節の治療. 日内分泌・甲状腺外会誌 35:162-172, 2018
 
3) Francis GL, et al.:Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 25:716-759, 2015
PubMed
4) 中野賢英, 他:機能性甲状腺結節に対するインターベンション治療 乳腺甲状腺超音波医 9:24-28, 2020
Medical*Online
5) Yano Y, et al.:Treatment of autonomously functioning thyroid nodules at a single institution:radioiodine therapy, surgery, and ethanol injection therapy. Ann Nucl Med 25:749-754, 2011
 
P.172 掲載の参考文献
1) Chang LS, et al.:Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. Endocr Rev 40:17-65, 2019
PubMed
2) 日本甲状腺学会:無痛性甲状腺炎の診断ガイドライン. 甲状腺疾患診断ガイドライン2021(2021年6月7日改定) http://www.japanthyroid.jp/doctor/guideline/japanese.html
 
3) Miyakawa M, et al.:Thyroid ultrasonography related to clinical and laboratory findings in patients with silent thyroiditis. J Endocrinol Invest 15:289-295, 1992
PubMed
4) 橘正 剛:亜急性甲状腺炎・無痛性甲状腺炎. 薬事 62:2511-2515, 2020
Medical*Online
P.173 掲載の参考文献
1) Kopp P, et al.:Brief report:congenital hyperthyroidism caused by a mutation in the thyrotropin-receptor gene. N Engl J Med 332:150-154, 1995
 
2) Thomas JS, et al.:Familial hyperthyroidism without evidence of autoimmunity. Acta Endocr (Copenh) 100:512-518, 1982
PubMed
3) Weinstein LS, et al.:Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Eng J Med 325:1688-1695, 1991
 
4) McCune DJ, et al.:Progress in pediatrics:osteodystrophia fibrosa. Am J Dis Child 54:806-848, 1937
 
5) Spaulding SW:Biological actions of thyrotropin. In:Braverman LE, et al.(eds):Werner & Ingbar's The Thyroid:a fundamental and clinical text. 9th ed, Lippincott Williams & Wilkins, Philadelphia, 183-197, 2005
 
6) de Roux N, et al.:A neomutation of the thyroid-stimulating hormone receptor in a severe neonatal hyperthyroidism. J Clin Endocr Metab 81:2023-2026, 1996
 
7) Corsi A, et al.:Neonatal McCune-Albright Syndrome:A Unique Syndromic Profile With an Unfavorable Outcome. JBMR Plus 3:e10134, 2019
PubMed
8) Lourenco R, et al.:Neonatal McCune-Albright syndrome with systemic involvement:a case report. J Med Case Rep 9:189, 2015
PubMed
9) Maruo Y, et al.:Successful every-other-day liothyronine therapy for severe resistance to thyroid hormone beta with a novel THRB mutation;case report. BMC Endocr Disord 16:1, 2016
PubMed
10) Merchant N, et al.:McCune-Albright Syndrome With Unremitting Hyperthyroidism at Early Age:Management Perspective for Early Thyroidectomy. Glob Pediatr Health 6:2333794X19875153, 2019
PubMed
P.174 掲載の参考文献
1) Matsuura N, et al.:The mechanisms of transient hypothyroxinemia in infants born to mothers with Graves' disease. Pediatr Res 42:214-218, 1997
PubMed
2) Huel C, et al.:Use of ultrasound to distinguish between fetal hyperthyroidism and hypothyroidism on discovery of a goiter. Ultrasound Obstet Gynecol 33:412-420, 2009
PubMed
3) Goldstein I, et al.:Ultrasonographic assessment of gestational age with the distal femoral and proximal tibial ossification centers in the third trimester. Am J Obstet Gynecol 158:127-30, 1988
PubMed
4) Funaki S, et al.:Ultrasonographic assessment of fetal thyroid in Japan:thyroid circumference and distal femoral and proximal tibial ossification. J Med Ultrason (2001) 47:603-608, 2020
PubMed
5) Nakano Y, et al.:Presumable suppression of fetal TSH lasting longer than 5-7 weeks after 22 weeks gestation is associated with risk of developing gestational graves' disease-related central hypothyroidism after birth. Int J Pregn & Chi Birth 4:39-43, 2018
 
Alexander EK, et al.:2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid 27:315-389, 2017
PubMed
日本甲状腺学会(編):バセドウ病治療ガイドライン2019, 南江堂, 2019
 
P.175 掲載の参考文献
1) Pearce EN, et al.:Thyroiditis. N Engl J Med 348:2646-2655, 2003
PubMed
2) Smith JR, et al.:Thyroiditis with pain. In:Kliegman RM, et al.(eds), Nelson Textbook of Pediatrics. 21st ed, Elsevier, Philadelphia, 2923, 2020
 
3) Campos-Barrera E, et al.:Subacute Thyroiditis Associated with COVID-19. Case Rep Endocrinol 2020:8891539, 2020
PubMed
4) 日本甲状腺学会:亜急性甲状腺炎(急性期)の診断ガイドライン. 甲状腺疾患診断ガイドライン2021. 2021 http:www.japanthyroid.jp/doctor/guideline/japanese.html
 
5) Takai SI, et al.:Internal fistula as a route of infection in acute suppurative thyroiditis. Lancet 1:751-752, 1979
PubMed
6) 土田嘉昭, 他:食道の先天奇形, 特にPyriform Sinus Fistulaについて. 日気管食道会報 38:506-511, 1987
 
P.177 掲載の参考文献
1) Morita, et al.:Risk Factors and Outcomes of Recurrent Pregnancy Loss in Japan. J Obstet Gyneacol Res 45:1997-2006, 2019
PubMed
2) Alexander EK, et al.:2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid 27:315-389, 2017
PubMed
3) Korevaar TI, et al.:Thyroid Autoimmunity Impairs the Thyroidal Response to Human Chorionic Gonadotropin:Two Population-Based Prospective Cohort Studies. J Clin Endocrinol Metab 102:69-77, 2017
PubMed
4) Negro R, et al.:Levothyroxine treatment in euthyroid pregnant women with autoimmune thyroid disease:effects on obstetrical complications. J Clin Endocrinol Metab 91:2587-2591, 2006
PubMed
5) Maraka S, et al.:Subclinical Hypothyroidism in Pregnancy:A Systematic Review and Meta-Analysis. Thyroid 26:580-590, 2016
PubMed
6) van den Boogaard E, et al.:Significance of (sub) clinical thyroid dysfunction and thyroid autoimmunity before conception and in early pregnancy: a systematic review. Hum Reprod Update 17:605-619, 2011
PubMed
7) 令和2年度厚生労働科学研究費補助金成育疾患克服等次世代育成基盤研究事業(健やか次世代育成総合研究事業分野)「不育症管理に関する提言」改訂委員会:不育症管理に関する提言2021. 2021
 
8) Yoshihara H, et al.:Levothyroxine and subclinical hypothyroidism in patients with recurrent pregnancy loss. Am J Reprod Immunol 85:e13341, 2021
PubMed
9) 日本甲状腺学会(編):バセドウ病治療ガイドライン2019, 南江堂, 2019
 
P.178 掲載の参考文献
1) Refetoff S, et al.:Familial syndrome combining deaf-mutism, stuppled epiphyses, goiter, and abnormally high PBI:possible target organ refractoriness to thyroid hormone. J Clin Endocrinol Metab 27:279-294, 1967
PubMed
2) Refetoff S, et al.:The syndrome of resistance to thyroid hormone. Endocr Rev 14:348-399, 1993
PubMed
3) Refetoff S, et al.:Syndrome of reduced sensitivity to thyroid hormone:genetic defects in hormone receptors, cell transporters and deiodination. Best Pract Res Endocrinol Metab 21:277-305, 2007
PubMed
4) Anselmo J, et al.:Fetal loss associated with excess thyroid hormone exposure. JAMA 292:691-695, 2004
PubMed
P.179 掲載の参考文献
1) Grijota- Martinez C, et al.:MCT8 Deficiency:The Road to Therapies for a Rare Disease. Front Neurosci 14:380, 2020
PubMed
2) Groeneweg S, et al.:Thyroid Hormone Transporters. Endocr Rev 41:146-201, 2020
 
3) Vancamp P, et al.:Monocarboxylate Transporter 8 Deficiency:Delayed or Permanent Hypomyelination? Front Endocrinol (Lausanne) 11:283, 2020
PubMed
4) Refetoff S, et al.:Prenatal Treatment of Thyroid Hormone Cell Membrane Transport Defect Caused by MCT8 Gene Mutation. Thyroid 31:713-720, 2021
PubMed
5) Groeneweg S, et al.:Disease characteristics of MCT8 deficiency:an international, retrospective, multicentre cohort study. Lancet Diabetes Endocrinol 8:594-605, 2020
PubMed
P.182 掲載の参考文献
1) 日本内分泌外科学会, 他(編):甲状腺癌取扱い規約. 第8版, 金原書店, 2019
 
2) 高野 徹:甲状腺癌の自然史と過剰診断発生のメカニズム. 日甲状腺会誌 12:22-27, 2021
 
3) 日本内分泌外科学会, 他(編):甲状腺腫瘍診療ガイドライン2018. 日内分泌・甲状腺外会誌 35(Suppl. 3), 10, 2018
 
4) Yan L, et al.:Ultrasound-Guided Radiofrequency Ablation Versus Thyroid Lobectomy for Low-Risk Papillary Thyroid Microcarcinoma:A Propensity-Matched Cohort Study of 884 Patients. Thyroid 31:1662-1672, 2021
PubMed
5) 和田修幸:小児の甲状腺腫瘍. 日甲状腺会誌 3:75-77, 2012
 
6) Sharma SC, et al.:Anaplastic Carcinoma Thyroid in a Young Child-an Extremely Rare Occurrence. Acta Medica (Hradec Kralove) 61:150-152, 2018
 
日本甲状腺学会(編):甲状腺専門医ガイドブック. 改訂第2版, 診断と治療社, 2018
 
American Thyroid Association Guidelines Task Force:Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 25:716-759, 2015
PubMed

第8章 カルシウムとビタミンD関連疾患

P.186 掲載の参考文献
1) Rubin LP:Disorders of calcium and phosphorus metabolism. In:Taeusch HW, et al.(eds), Avery's Diseases of the Newborn. 8th ed, Saunders(Elsevier), Philadelphia, 1346-1363, 2005
 
2) Fukumoto S, et al.:Causes and differential diagnosis of hypocalcemia-recommendation proposed by expert panel supported by ministry of health, labor, and welfare, Japan. Endocr J 55:787-794, 2008
 
3) Rigo J, et al.:Entral calcium, phosphate, and vitamin D requirements and bone mineralization in preterm infants. Acta Paediatr 96:969-974, 2007
 
4) Isojima T, et al.:Mineral status of premature infants in early life and linear growth at age three. Pediatr Int 57:864-869, 2015
 
P.188 掲載の参考文献
1) Pepe J, et al.:Diagnosis and management of hypocalcemia. Endocrine 69:485-495, 2020
PubMed
2) 荻原康子:低カルシウム血症. 日本小児内分泌学会(編), 小児内分泌学. 改訂第3版, 診断と治療社, 133-136, 2022
 
3) Goltzman D:Treatment of hypocalcemia (Ver. 37.0). In:UpToDate, Wolters Kluwer, Philadelphia, Last Update:Mar 12, 2021
 
4) Yu ASL, et al.:Evaluation and treatment of hypomagnesemia (Ver. 27.0). In:UpToDate, Wolters Kluwer, Philadelphia, Last Update:May 25, 2021
 
5) Vuralli D:Clinical approach to hypocalcemia in newborn period and infancy:Who should be treated? Int J Pediatr 2019, 4318075, 2019
PubMed
6) Payne RB, et al.:Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J 4:643-646, 1973
PubMed
7) Abrams SA:Neonatal hypocalcemia (Ver. 18.0). In:UpToDate, Wolters Kluwer, Philadelphia, Last Update:May 19, 2020
 
Lexicomp(R):Calcium gluconate:Pediatric drug information (Ver. 242.0). In:Lexicomp(R), Wolters Kluwer, Philadelphia
 
上村克徳:ナトリウム, カリウム, クロール, カルシウム, リン, マグネシウム. 小児内科 49(増刊号):233-242, 2017
 
河合 忠:カルシウム(Ca)とカルシウムイオン, マグネシウム(Mg). 河合 忠, 他(編), 異常値の出るメカニズム. 第6版, 医学書院, 224-233, 2013
 
P.192 掲載の参考文献
1) Fukumoto S, et al.:Causes and differential diagnosis of hypocalcemia-recommendation proposed by expert panel supported by ministry of health, labour and welfare, Japan. Endocr J 55:787-794, 2008
 
2) 難病情報センター:副甲状腺機能低下症(指定難病 235). https://www.nanbyou.or.jp/entry/4427
 
3) 日本医学会:医療における遺伝学的検査・診断に関するガイドライン(2022年3月改訂). 2022 https://jams.med.or.jp/guideline/genetics-diagnosis_2022.pdf
 
4) Gafni RI, et al.:Hypoparathyroidism. N Engl J Med 380:1738-1747, 2019
PubMed
5) Hannan FM, et al.:The calcium-sensing receptor in physiology and in calcitropic and noncalcitropic diseases. Nat Rev Endocrinol 15:33-51, 2018
PubMed
6) Alexander RT, et al.:Effect of diuretics on renal tubular transport of calcium and magnesium. Am J Physiol Renal Physiol 312:F998-F1015, 2017
PubMed
7) Reilly RF, et al.:The mechanism of hypocalciuria with NaCl cotransporter inhibition. Nat Rev Nephrol 7:669-674, 2011
PubMed
8) Brandi ML, et al.:Management of hypoparathyroidism:summary statement and guidelines. J Clin Endocrinol Metab 101:2273-2283, 2016
PubMed
9) 「日本人の食事摂取基準」策定検討会:日本人の食事摂取基準(2020年版):「日本人の食事摂取基準」策定検討会報告書. 2020 https://www.mhlw.go.jp/content/10904750/000586553.pdf
 
10) Munns CF, et al.:Global Consensus Recommendations on Prevention and Management of Nutritional Rickets. J Clin Endocrinol Metab 101:394-415, 2016
PubMed
11) Bilezikian JP:Hypoparathyroidism. J Clin Endocrinol Metab 105:1722-1736, 2020
PubMed
12) Mannstadt M, et al.:Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism(REPLACE):a double-blind, placebo-controlled, randomised, phase 3 study. Lancet Diabetes Endocrinol 1:275-283, 2013
PubMed
13) Sastre A, et al.:PTH Infusion for Seizures in Autosomal Dominant Hypocalcemia Type 1. N Engl J Med 385:189-191, 2021
PubMed
P.195 掲載の参考文献
1) Fukumoto S, et al.:Causes and differential diagnosis of hypocalcemia-recommendation proposed by expert panel supported by ministry of health, labour and welfare, Japan. Endocr J 55:787-794, 2008
 
2) Mantovani G, et al.:Diagnosis and management of pseudohypoparathyroidism and related disorders:first international Consensus Statement. Nat Rev Endocrinol 14:476-500, 2018
PubMed
3) 尾形悦郎, 他:ヒト PTH-(1-34)によるEllsworth-Howard試験の実施法と判定基準副甲状腺機能低下症患者における検討. 日内分泌会誌 60:971-984, 1984
 
4) 日本医学会:医療における遺伝学的検査・診断に関するガイドライン(2022年3月改訂). 2022 https://jams.med.or.jp/guideline/genetics-diagnosis_2022.pdf
 
5) 「日本人の食事摂取基準」策定検討会:日本人の食事摂取基準(2020年版):「日本人の食事摂取基準」策定検討会報告書. 2020 https://www.mhlw.go.jp/content/10904750/000586553.pdf
 
6) Munns CF, et al.:Global Consensus Recommendations on Prevention and Management of Nutritional Rickets. J Clin Endocrinol Metab 101:394-415, 2016
PubMed
7) Underbjerg L, et al.:Pseudohypoparathyroidism-epidemiology, mortality and risk of complications. Clin Endocrinol(Oxf) 84:904-911, 2016
PubMed
P.197 掲載の参考文献
1) Holick MF:Resurrection of vitamin D deficiency and rickets. J Clin Invest 116:2062-2072, 2006
PubMed
2) Misra M, et al.:Vitamin D deficiency in children and its management:review of current knowledge and recommendations. Pediatrics 122:398-417, 2008
PubMed
3) 日本小児内分泌学会:ビタミンD欠乏性くる病・低カルシウム血症の診断の手引き. 2013年 http://jspe.umin.jp/medical/files/_vitaminD.pdf
 
4) Holick MF, et al.:Evaluation, treatment, and prevention of vitamin D deficiency:an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:1911-1930, 2011
PubMed
5) Amrein K, et al.:Vitamin D deficiency 2.0:an update on the current status worldwide. Eur J Clin Nutr 74:1498-1513, 2020
PubMed
6) Munns CF, et al.:Global Consensus Recommendations on Prevention and Management of Nutritional Rickets. J Clin Endocrinol Metab 101:394-415, 2016
PubMed
7) Kubota T, et al.:Serum fibroblast growth factor 23 is a useful marker to distinguish vitamin D-deficient rickets from hypophosphatemic rickets. Horm Res Paediatr 81:251-257, 2014
PubMed
P.200 掲載の参考文献
1) The HYP Consortium:A gene(PEX)with homologies to endopeptidases in mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 11:130-136, 1995
 
2) Fukumoto S, et al.:Pathogenesis and diagnostic criteria for rickets and osteomalacia-Proposal by an expert panel supported by Ministry of Health, Labour and Welfare, Japan, The Japanese Society for Bone and Mineral Research and The Japan Endocrine Society [Opinion]. Endocr J 62:665-671, 2015
Medical*Online
3) Haffner, et al.:Clinical practice recommendations for the diagnosis and management of X-linked hypophosphatamia. Nat Rev Nephrol 15:435-455, 2019
 
4) Carpenter TO, et al.:Burosumab therapy in children with X-linked hypophosphatemia. N Engl J Med 378:1987-1998, 2018
PubMed
5) Imel EA, et al.:Burosumab versus conventional therapy in children with X-linked hypophosphataemia:a ramdomized, active-controlled, open-label, phase 3 trial. Lancet 393:2416-2427, 2019
 
P.201 掲載の参考文献
1) Kitanaka S, et al.:Inactivating mutations in the 25-hydroxyvitamin D3 1α-hydroxylase gene in patients with pseudovitamin D-deficiency rickets. N Engl J Med 338:653-661, 1998
 
2) Glorieux FH, et al.:Pseudo-vitamin D deficiency. In:Feldman D, et al.(eds), Vitamin D. 3rd ed, Academic Press(Elsevier), Amsterdam, 1187-1195, 2011
 
3) Cheng JB, et al.:Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc Natl Acad Sci U S A 101:7711-7715, 2004
PubMed
P.203 掲載の参考文献
1) Hughes MR, et al.:Point mutations in the human vitamin D receptor gene associated with hypocalcemic rickets. Science 242:1702-1705, 1988
PubMed
2) Malloy PJ, et al.:Vitamin D receptor mutations in patients with hereditary 1, 25-dihydroxyvitamin D-resistant rickets. Mol Genet Metab 111:33-40, 2014
PubMed
3) Malloy PJ, et al.:Hereditary vitamin D-resistant rickets(HVDRR) owing to a heterozygous mutation in the vitamin D receptor. J Bone Miner Res 26:2710-2718, 2011
PubMed
4) Malloy PJ, et al.:Hereditary 1, 25-dihydroxyvitamin D resistant rickets. In:Feldman D, et al.(eds), Vitamin D. 3rd ed, Academic Press(Elsevier), Amsterdam, 1197-1232, 2011
 
5) Bikle D, et al.:New aspects of vitamin D metabolism and action - addressing the skin as source and target. Nat Rev Endocrinol 16:234-252, 2020
PubMed
P.204 掲載の参考文献
1) Roizen JD, et al.:CYP3A4 mutation causes vitamin D-dependent rickets type 3. J Clin Invest 128:1913-1918, 2018
 
P.205 掲載の参考文献
1) Heubi JE, et al.:Bone disease in chronic childhood cholestasis. I. vitamin D absorption and metabolism.Hepatology 9:258-264, 1989
PubMed
2) Cebesi AN, et al.:Epilepsy treatment by sacrificing vitamin D. Expert Rev Neurother 14:481-491, 2014
 
P.206 掲載の参考文献
1) CKD診療ガイド・ガイドライン改訂委員会:小児CKDにCKD-MBDの管理は推奨されるか? 日本腎臓学会(編), エビデンスに基づくCKD診療ガイドライン2018. 東京医学社, 69-71, 2018
 
P.208 掲載の参考文献
1) Root AW, et al.:Disorders of mineral homeostasis in children and adolescents. In:Sperling MA(ed), Pediatric Endocrinology. 4th ed, Saunders(Elsevier), Philadelphia, 734-845, 2014
 
2) Stokes VJ, et al.:Hypercalcemic Disorders in Children. J Bone Miner Res 32:2157-2170, 2017
 
3) Eastell R, et al.:Diagnosis of asymptomatic primary hyperparathyroidism:proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 99:3570-3579, 2014
PubMed
4) Davies JH:Approach to the Child with Hypercalcaemia. Endocr Dev 28:101-118, 2015
 
5) Auron A, et al.:Hypercalcemia:a consultant's approach. Pediatr Nephrol 33:1475-1488, 2018
PubMed
P.210 掲載の参考文献
1) Walker MD, et al.:Primary hyperparathyroidism. Nat Rev Endocrinol 14:115-125, 2018
PubMed
2) Bilezikian JP:Primary Hyperparathyroidism. J Clin Endocrinol Metab 103:3993-4004, 2018
PubMed
3) Roizen J, et al.:Primary hyperparathyroidism in children and adolescents. J Chin Med Assoc 75:425-434, 2012
PubMed
4) Alagaratnam S, et al.:Aetiology, Diagnosis and Surgical Treatment of Primary Hyperparathyroidism in Children:New Trends. Horm Res Paediatr 83:365-375, 2015
 
5) Belcher R, et al.:Characterization of hyperparathyroidism in youth and adolescents:a literature review. Int J Pediatr Otorhinolaryngol 77:318-322, 2013
PubMed
6) Hannan FM, et al.:The calcium-sensing receptor in physiology and in calcitropic and noncalcitropic diseases. Nat Rev Endocrinol 15:33-51, 2018
PubMed
P.211 掲載の参考文献
1) Glorieux FH:Osteogenesis imperfecta. A disease of the osteoblast. Lancet 358 Suppl:S45, 2001
 
2) Claeys L, et al.:Collagen transport and related pathways in Osteogenesis Imperfecta. Hum Genet 140:1121-1141, 2021
PubMed
3) Sillence DO, et al.:Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 16:101-116, 1979
PubMed
4) Van Dijk FS, et al.:Classification of Osteogenesis Imperfecta revisited. Eur J Med Genet 53:1-5, 2010
PubMed
5) Warman ML, et al.:Nosology and classification of genetic skeletal disorders:2010 revision. Am J Med Genet A 155A:943-968, 2011
PubMed
6) Bonafe L, et al.:Nosology and classification of genetic skeletal disorders:2015 revision. Am J Med Genet A 167A:2869-2892, 2015
PubMed
7) Mortier GR, et al.:Nosology and classification of genetic skeletal disorders:2019 revision. Am J Med Genet A 179:2393-2419, 2019
PubMed
8) OMIM(R)(Online Mendelian Inheritance in Man(R)) https://www.omim.org
 
9) 難病情報センター:骨形成不全症(指定難病 274). https://www.nanbyou.or.jp/entry/4568
 
10) Glorieux FH, et al.:Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339:947-952, 1998
PubMed
11) 田中弘之, 他:骨形成不全症の診療ガイドライン. 日小児会誌 110:1468-1471, 2006
 
12) Munns CF, et al.:Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. Bone 35:231-234, 2004
PubMed
13) Dwan K, et al.:Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev 10:CD005088, 2016
PubMed
14) Whyte MP, et al.:Bisphosphonate-induced osteopetrosis. N Engl J Med 349:457-463, 2003
PubMed
15) Japanese Allied Committee on Osteonecrosis of the Jaw, et al.:Antiresorptive agent-related osteonecrosis of the jaw:Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. J Bone Miner Metab 35:6-19, 2017
 
16) Contaldo M, et al.:Bisphosphonate-related osteonecrosis of the jaws and dental surgery procedures in children and young people with osteogenesis imperfecta:A systematic review. J Stomatol Oral Maxillofac Surg 121:556-562, 2020
 
P.213 掲載の参考文献
1) Whyte MP:Hypophosphatasia:An overview For 2017. Bone 102:15-25, 2017
PubMed
2) Michigami T, et al.:Clinical Practice Guidelines for Hypophosphatasia. Clin Pediatr Endocrinol 29:9-24, 2020 https://minds.jcqhc.or.jp/docs/gl_pdf/G0001124/4/Hypophospha-tasia_Clinical_practice_guidelines.pdf
 
3) Michigami T, et al.:Common mutations F310L and T1559del in the tissue-nonspecific alkaline phosphatase gene are related to distinct phenotypes in Japanese patients with hypophosphatasia. Eur J Pediatr 164:277-282, 2005
PubMed
4) Whyte MP, et al.:Hypophosphatasia:validation and expansion of the clinical nosology for children from 25 years experience with 173 pediatric patients. Bone 75:229-239, 2015
PubMed
5) Stockler S, et al.:Pyridoxine dependent epilepsy and antiquitin deficiency:clinical and molecular characteristics and recommendations for diagnosis, treatment and follow-up. Mol Genet Metab 104:48-60, 2011
PubMed
6) 難病情報センター:低ホスファターゼ症(指定難病 172)-診断・治療方針 https://www.nanbyou.or.jp/entry/4565
 
7) Akiyama T, et al.:Pyridoxal 5'-phosphate and related metabolites in hypophosphatasia:Effects of enzyme replacement therapy. Mol Genet Metab 125:174-180, 2018
PubMed
8) Watanabe A, et al.:Prevalence of c.1559delT in ALPL, a common mutation resulting in the perinatal (lethal) form of hypophosphatasia in Japanese and effects of the mutation on heterozygous carriers. J Hum Genet 56:166-168, 2011
PubMed
9) Michigami T, et al.:Hypophosphatasia in Japan:ALPL Mutation Analysis in 98 Unrelated Patients. Calcif Tissue Int 106:221-231, 2020
PubMed
10) Whyte MP, et al.:Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med 366:904-913, 2012
PubMed
11) Whyte MP, et al.:Asfotase Alfa Treatment Improves Survival for Perinatal and Infantile Hypophosphatasia. J Clin Endocrinol Metab 101:334-342, 2016
PubMed

第9章 糖代謝異常症

P.225 掲載の参考文献
1) Wolfsdorf JI, et al.:ISPAD Clinical Practice Consensus Guidelines 2018:Diabetic ketoacidosis and the hyperglycemic hyperosmolar state. Pediatr Diabetes 19 (Suppl. 27):155-177, 2018
 
2) Danne T, et al.:ISPAD Clinical Practice Consensus Guidelines 2018:Insulin treatment in children and adolescents with diabetes. Pediatr Diabetes 19 (Suppl. 27):115-135, 2018
 
3) 広瀬正和, 他:乳幼児期発症の糖尿病患者においてインスリン持続皮下注入療法(CSII)とカーボカウント法により良好な経過をとった3例. 糖尿病 50:811-817, 2007
 
4) Adolfsson P, et al.:ISPAD Clinical Practice Consensus Guidelines 2018:Exercise in children and adolescents with diabetes. Pediatr Diabetes 19 (Suppl. 27):205-226, 2018
 
5) DiMeglio LA, et al.:ISPAD Clinical Practice Consensus Guidelines 2018:Glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes. Pediatr Diabetes 19 (Suppl. 27):105-114, 2018
 
6) Laffel LM, et al.:ISPAD Clinical Practice Consensus Guidelines 2018:Sick day management in children and adolescents with diabetes. Pediatr Diabetes 19 (Suppl. 27):193-204, 2018
 
7) 糖尿病性腎症合同委員会:糖尿病性腎症病期分類2014の策定(糖尿病性腎症病期分類改訂)について. 糖尿病 57:529-534, 2014
 
8) Asao K, et al.:Long-term mortality in nationwide cohorts of childhood-onset type 1 diabetes in Japan and Finland. Diabetes Care 26:2037-2042, 2003
PubMed
9) Otani T, et al. :Changes in the prognosis of Japanese patients who developed type 1 diabetes before the age of 30 years. Diabetes Res Clin Pract 109:434-439, 2015
PubMed
日本糖尿病学会(編):糖尿病専門医研修ガイドブック. 改訂第8版, 診断と治療社, 2020
 
日本糖尿病学会(編著):糖尿病診療ガイドライン2019. 南江堂, 2019
 
P.238 掲載の参考文献
1) Urakami T, et al.:Urine glucose screening program at schools in Japan to detect children with diabetes and its outcome-incidence and clinical characteristics of childhood type 2 diabetes in Japan. Pediatr Res 61:141-145, 2007
PubMed
2) Urakami T, et al.:Changes in annual incidence of school children with type 2 diabetes in the Tokyo Metropolitan Area during 1975-2015. Pediatr Diabetes 19:1385-1392, 2018
 
3) 文部科学省総合教育政策局調査企画課:平成30年度学校保健統計(学校保健統計調査報告書)の公表について. 2019 https://www.mext.go.jp/component/b_menu/other/__icsFiles/afieldfile/2019/03/25/1411703_01.pdf
 
4) 日本糖尿病学会:糖尿病の分類と診断基準に関する委員会報告(国際標準化対応版). 糖尿病 55:492, 2012
 
5) 学校保健会:学校検尿と糖尿病. 学校検尿のすべて. 令和2年度改訂, 学校保健協会, 93-94, 2021
 
6) Sugihara S, et al.:Survey of current medical treatments for childhood-onset type 2 diabetes mellitus in Japan. Clin Pediatr Endocrinol 14:65-75, 2005
PubMed
7) 菱田 明, 他(監修):日本人の食事摂取基準(2020年版). 第一出版, 2020
 
8) Zeitler P, et al.:ISPAD Clinical Practice Consensus Guidelines 2018:Type 2 diabetes mellitus in youth. Pediatr Diabetes 19 (Suppl. 27):28-46, 2018
 
9) 日本糖尿病学会(編著):糖尿病治療ガイド2020-2021. 文光堂, 2020
 
10) Matsuura N, et al.:Metformin monotherapy in children and adolescents with type 2 diabetes mellitus in Japan. Diabetol Int 10:51-57, 2018
PubMed
11) Zeitler P, et al.:A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med 366:2247-2256, 2012
PubMed
12) Zeitler P, et al.:Treatment options for type 2 diabetes in adolescents and youth:a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes. Pediatr Diabetes 8:74-87, 2007
 
13) American Diabetes Association:9. Pharmacologic Approaches to Glycemic Treatment:Standards of Medical Care in Diabetes-2021. Diabetes Care 44 (Suppl. 1):S111-S124, 2021
 
14) 日本肥満学会(編):小児肥満症診療ガイドライン2017. ライフサイエンス出版, 2017
 
15) Klingensmith GJ, et al.:Presentation of youth with type 2 diabetes in the Pediatric Diabetes Consortium. Pediatr Diabetes 17:266-273, 2016
PubMed
16) Kitabchi AE, et al.:Hyperglycemia crises in adult patients with diabetes. Diabetes Care 32:1335-1343, 2009
PubMed
17) Zeitler P, et al.:Hyperglycemic hyperosmolar syndrome in children:pathophysiological considerations and suggested guidelines for treatment. J Pediatr 158:9-14, 14.e1-14.e2, 2011
 
18) Wolfsdorf JI, et al.:ISPAD Clinical Practice Consensus Guidelines 2018: Diabetic ketoacidosis and the hyperglycemic hyperosmolar state. Pediatr Diabetes 19 (Suppl. 27):155-177, 2018
 
P.241 掲載の参考文献
1) 日本内分泌学会(編):内分泌代謝科専門医研修ガイドブック. 診断と治療社, 623-625, 2018
 
2) Hattersley AT, et al.:ISPAD Clinical Practice Consensus Guidelines 2018:The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes 19 (Suppl. 27):47-63, 2018
 
3) Clissold RL, et al.:HNF1B-associated renal and extra-renal disease-an expanding clinical spectrum. Nat Rev Nephrol 11:102-112, 2015
PubMed
4) Ostoft SH, et al.:Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist:a double-blind, randomized, crossover trial. Diabetes Care 37:1797-1805, 2014
PubMed
5) 浦上達彦, 他:MODY3に対するGLP-1受容体作動薬の有用性に関する検討. ホルモンと臨 59:1035-1038, 2011
 
6) Steele AM, et al.:Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia. JAMA 311:279-286, 2014
PubMed
P.242 掲載の参考文献
Chow J, et al.:Mitochondrial disease and endocrine dysfunction. Nat Rev Endocrinol 13:92-104, 2017
PubMed
日本糖尿病学会, 他(編):小児・思春期糖尿病コンセンサス・ガイドライン. 南江堂, 2015
 
日本ミトコンドリア学会(編):ミトコンドリア病診療マニュアル2017. 診断と治療社, 2016
 
P.243 掲載の参考文献
1) Takeyari S, et al.:Metreleptin treatment for congenital generalized lipodystrophy type 4 (CGL4): a case report. Clin Pediatr Endocrinol 28: 1-7, 2019
PubMed
P.244 掲載の参考文献
1) Hattersley AT, et al.:ISPAD Clinical Practice Consensus Guidelines 2018:The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes 19 (Suppl. 27):47-63, 2018
 
2) 依藤 亨:小児糖尿病と遺伝子異常. 糖尿病 62:464-467, 2019
 
3) Beltrand J, et al.:Neonatal Diabetes Mellitus. Front Pediatr 8:540718, 2020
PubMed
4) Hashimoto Y, et al.:Molecular and clinical features of KATP-channel neonatal diabetes mellitus in Japan. Pediatr Diabetes 18:532-539, 2017
PubMed
5) Dahl A, et al.:Recent Advances in Neonatal Diabetes. Diabetes Metab Syndr Obes 13:355-364, 2020
PubMed
6) Pearson ER, et al.:Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 355:467-477, 2006
PubMed
P.246 掲載の参考文献
1) Geer EB, et al.:Mechanisms of glucocorticoid-induced insulin resistance:focus on adipose tissue function and lipid metabolism. Endocrinol Metab Clin North Am 43:75-102, 2014
PubMed
2) American Diabetes Association:2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes-2021. Diabetes Care 44 (Suppl. 1):S15-S33, 2021
 
3) American Diabetes Association:6. Glycemic Targets:Standards of Medical Care in Diabetes-2021. Diabetes Care 44 (Suppl. 1):S73-S84, 2021
 
4) Suh S, et al.:Glucocorticoid-Induced Diabetes Mellitus:An Important but Overlooked Problem. Endocrinol. Metab(Seoul) 32:180-189, 2017
PubMed
5) Roberts A, et al.:Management of hyperglycaemia and steroid (glucocorticoid) therapy:a guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care group. Diabet Med 35:1011-1017, 2018
PubMed
6) Wallace MD, et al.:Optimizing the Treatment of Steroid-Induced Hyperglycemia. Ann Pharmacother 52:86-90, 2018
PubMed
7) Tamez- Perez HE, et al.:Steroid hyperglycemia:Prevalence, early detection and therapeutic recommendations:A narrative review. World J Diabetes 6:1073-1081, 2015
PubMed
8) Clore JN, et al.:Glucocorticoid-induced hyperglycemia. Endocr Pract 15:469-474, 2009
PubMed
9) Aberer F, et al.:A Practical Guide for the Management of Steroid Induced Hyperglycaemia in the Hospital. J Clin Med 10: 2154, 2021
PubMed
P.247 掲載の参考文献
日本小児内分泌学会, 他:先天性高インスリン血症診療ガイドライン. 2016 http://jspe.umin.jp/medical/files/guide161004.pdf
 
Yorifuji T:Congenital hyperinsulinism:current status and future perspectives. Ann Pediatr Endocrinol Metab 19:57-68, 2014
 
Yamada Y, et al.:Nationwide survey of endogenous hyperinsulinemic hypoglycemia in Japan (2017-2018):Congenital hyperinsulinism, insulinoma, non-insulinoma pancreatogenous hypoglycemia syndrome and insulin autoimmune syndrome(Hirata's disease). J Diabetes Investig 11:554-563, 2020
 
P.248 掲載の参考文献
1) 加計 剛:インスリノーマ. 別冊日本臨牀 内分泌症候群IV-その他の内分泌疾患を含めて-. 第3版, 日本臨牀社, 209-212, 2019.
 
2) Okabayashi T, et al.:Diagnosis and management of insulinoma. World J Gastroenterol 19:829-837, 2013
 
3) 小杉眞司: Wermer症候群(多発性内分泌腫瘍症1型:MEN1). 小児科診療 79(Suppl.):261, 2016
 
4) 日本神経内分泌腫瘍研究会(JNETS)(編):膵・消化管神経内分泌腫瘍(NEN)診療ガイドライン. 第2版, 金原出版, 2019
 
5) 日本小児内分泌学会, 他:血糖管理目標・初期治療, セカンドライン治療. 先天性高インスリン血症診療ガイドライン. 12-19, 2016 http://jspe.umin.jp/medical/files/guide161004.pdf
 
6) Yamada Y, et al.:Nationwide survey of endogenous hyperinsulinemic hypoglycemia in Japan (2017-2018):Congenital hyperinsulinism, insulinoma, non-insulinoma pancreatogenous hypoglycemia syndrome and insulin autoimmune syndrome(Hirata's disease). J Diabetes Investig 11:554-563, 2020
 
P.249 掲載の参考文献
都 研一:ケトン性低血糖症. 日本小児内分泌学会(編), 小児内分泌学. 改訂第3版, 診断と治療社, 568-569, 2022
 
Sperling MA:Ketotic hypoglycemia. In:Kliegman RM, et al. (eds), Nelson Textbook of Pediatrics. 19th ed, Saunders(Elsevier), Philadelphia, 528, 2011
 
P.251 掲載の参考文献
1) 日本糖尿病・妊娠学会と日本糖尿病学会との合同委員会:妊娠中の糖代謝異常と診断基準の統一化について. 糖尿病 58:801-803, 2015
 
2) 日本糖尿病学会(編):糖尿病と妊娠. 糖尿病専門医研修ガイドブック. 改訂第8版, 診断と治療社, 377-382, 2020
 
3) 内潟安子:糖尿病があっても妊娠できますか. 妊娠するのに好ましい糖尿病の状態は? 日本糖尿病・妊娠学会(編), 妊婦の糖代謝異常 診療・管理マニュアル. 改訂第2版, メジカルビュー社, 25-26, 2018
 
4) 日本糖尿病学会(編著):糖尿病患者の妊娠前管理をどのように行うか? 糖尿病診療ガイドライン2019. 南江堂, 288-291, 2019
 
5) 日本糖尿病学会(編著):糖代謝異常妊婦の妊娠中管理目標はどう設定すべきか? 糖尿病診療ガイドライン2019. 南江堂, 291-294, 2019
 
6) 日本糖尿病学会(編著):糖代謝異常妊婦の妊娠中管理をどのように行うか? 糖尿病診療ガイドライン2019. 南江堂, 295-297, 2019
 
7) 正岡直樹, 他:糖尿病合併妊娠, 妊娠糖尿病で起こりやすい母体合併症は? 日本糖尿病・妊娠学会(編), 妊婦の糖代謝異常 診療・管理マニュアル. 改訂第2版, メジカルビュー社, 69-71, 2018
 
P.253 掲載の参考文献
1) Pedersen J:Weight and length at birth of infants of diabetes mothers. Acta Endocrinol (Copenh) 16:330-342, 1954
PubMed
2) Guerin A, et al.:Use of maternal GHb concentrations to estimate the risk of congenital anomalies in the offspring of women with pregnancy diabetes. Diabetes Care 30:1920-1925, 2007
PubMed
3) 和栗雅子:妊娠糖尿病と先天奇形. 藤田富雄, 他(編), 「妊娠と糖尿病」診療スタンダード. 金芳堂, 253-259, 2002
 
4) Aberg A, et al.:Congenital malformations among infants whose mothers had gestational diabetes or preexisting diabetes. Early Hum Dev 61:85-95, 2001
PubMed
5) Eriksson UJ, et al.:Pathogenesis of diabetes-induced congenital malformations. Ups J Med Sci 105:53-84, 2000
PubMed
6) Weindling AM:Offspring of diabetic pregnancy:short-term outcomes. Semin Fatal Neonatal Med 14:111-118, 2009
 
7) Opati P, et al:Comparison of neonatal outcomes ill macrosomic infants of diabetic and non-diabetic mothers. J Neonatal Perinatal Med 8:9-13, 2015
 
8) 石井徹子, 他:糖尿病母体児と肥大型心筋症. 周産期医学 33:571-573, 2003
 

第10章 肥満・脂質代謝異常症

P.262 掲載の参考文献
1) 菊池 透, 他:肥満, メタボリックシンドロームと脂質異常症. 日本小児内分泌学会(編), 小児内分泌学. 改訂第3版, 診断と治療社, 571-588, 2022
 
2) 日本肥満学会(編):小児肥満症診療ガイドライン2017. ライフサイエンス出版, 2017
 
3) 日本成長学会・日本小児内分泌学会合同標準値委員会:日本人小児の体格の評価. 2011 http://jspe.umin.jp/medical/taikaku.html
 
4) Yoshii K, et al.:Reduced pubertal growth in children with obesity regardless of pubertal timing. Endocr J 67:477-484, 2020
PubMed
5) 菊池 透:肥満とメタボリックシンドローム. 横谷進, 他(編), 専門医による新小児内分泌疾患の治療. 改訂第2版, 診断と治療社, 250-261, 2017
 
6) 菊池 透:肥満症. 伊藤秀一(編), 小児科コモン 60 疾患実践的ガイドライン活用術. 中山書店, 283-289, 2019
 
7) 菊池 透:子どもの肥満の食事療法. チャイルドヘルス 11:85-90, 2008
Medical*Online
8) 足達淑子:行動療法に基づいた指導とはどのようなものか. ライフスタイル療法II肥満の行動療法, 医歯薬出版, 1-27, 2006
 
9) 菊池 透:乳幼児期から学童期:その身体的変化と糖尿病診療におけるコツ. 糖尿病プラクティス 38:526-534, 2021
Medical*Online
10) Kelly AS, et al.:A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. N Engl J Med 382, 2117-2128. 2020
PubMed
11) 朝山光太郎:小児肥満の疫学. 大関武彦(編), 小児メタボリックシンドローム, 中山書店, 126-129, 2009
 
P.265 掲載の参考文献
1) 日本動脈硬化学会:動脈硬化性疾患予防ガイドライン2017年版. 日本動脈硬化学会, 2017
Medical*Online
2) 日本動脈硬化学会:動脈硬化性疾患予防のための脂質異常症診療ガイド2018年版. 日本動脈硬化学会, 2018
Medical*Online
3) 日本肥満学会(編):小児肥満症診療ガイドライン2017. ライフサイエンス出版, 2017
 
4) Dobashi K:Changes in Serum Cholesterol in Childhood and its Tracking to Adulthood. J Atheroscler Thromb 29:5-7, 2022
PubMed
5) 日本小児科学会, 他(編):小児家族性高コレステロール血症診療ガイド2017. 日本動脈硬化学会, 2017
 
6) Wiegman A, et al.:Familial hypercholesterolaemia in children and adolescents:gaining decades of life by optimizing detection and treatment. Eur Heart J 36:2425-2437, 2015
PubMed
7) Luirink IK, et al.:Efficacy and safety of lipoprotein apheresis in children with homozygous familial hypercholesterolemia:A systematic review. J Clin Lipidol 13:31-39, 2019
PubMed

第11章 尿細管障害

P.271 掲載の参考文献
1) Trepiccione F, et al.:Distal renal tubular acidosis:ERKNet/ESPN clinical practice points. Nephrol Dial Transplant 36:1585-1596, 2021
PubMed
2) Goules A, et al.:Renal involvement in primary Sjogren's syndrome:natural history and treatment outcome. Clin Exp Rheumatol 37 Suppl 118:123-132, 2019
 
3) Palmer BF, et al.:Renal tubular acidosis and management strategies:a narrative review. Adv Ther 38:949-968, 2021
PubMed
4) Wesson DE, et al.:Veverimer versus placebo in patients with metabolic acidosis associated with chronic kidney disease:a multicentre, randomised, double-blind, controlled, phase 3 trial. Lancet 393:1417-1427, 2019
PubMed
5) Bertholet-Thomas A, et al.:Efficacy and safety of an innovative prolonged-release combination drug in patients with distal renal tubular acidosis:an open-label comparative trial versus standard of care treatments. Pediatr Nephrol 36:83-91, 2021
PubMed
6) Lopez-Garcia SC, et al.:Treatment and long-term outcome in primary distal renal tubular acidosis. Nephrol Dial Transplant 34:981-991, 2019
PubMed
7) Foreman JW:Fanconi Syndrome. Pediatr Clin North Am 66:159-167, 2019
PubMed
P.275 掲載の参考文献
1) Konrad M, et al.:Diagnosis and management of Bartter syndrome:executive summary of the consensus and recommendations from the European Rare Kidney Disease Reference Network Working Group for Tubular Disorders. Kidney Int 99:324-335, 2021
 
2) Blanchard A, et al.:Gitelman syndrome:consensus and guidance from a Kidney Disease:Improving Global Outcomes(KDIGO)Controversies Conference. Kidney Int 91:24-33, 2017
PubMed
3) Yang X, et al.:Bartter syndrome type 3:phenotype-genotype correlation and favorable response to ibuprofen. Front Pediatr 6:153, 2018
PubMed
4) Blanchard A, et al.:Indomethacin, amiloride, or eplerenone for treating hypokalemia in Gitelman syndrome. J Am Soc Nephrol 26:468-475, 2015
PubMed
5) Bhat YR, et al.:Antenatal Bartter syndrome:a rare cause of unexplained severe polyhydramnios. Ann Trop Paediatr 31:153-157, 2011
PubMed
6) Mazaheri M, et al.:Adjunctive acetazolamide therapy for the treatment of Bartter syndrome. Int Urol Nephrol 52:121-128, 2020
PubMed
7) Puricelli E, et al.:Long-term follow-up of patients with Bartter syndrome type I and II. Nephrol Dial Transplant 25:2976-2981, 2010
PubMed
P.278 掲載の参考文献
1) Belot A, et al.:Pseudohypoaldosteronisms, report on a 10-patient series. Nephrol Dial Transplant 23:1636-1641, 2008
PubMed
2) Diaz-Thomas:Pseudohypoaldosteronism Treatment & Management. Medscape, 2017 https://emedicine.medscape.com/article/924100-treatment
 
3) Adachi M, et al.:Dietary potassium restriction attenuates urinary sodium wasting in the generalized form of pseudohy-poaldosteronism type 1. CEN Case Rep 9:133-137, 2020
PubMed
4) Gordon DB:Some early investigations of experimental hypertension. An historical review. Tex Rep Biol Med 28:179-188, 1970
PubMed
5) 熊谷直憲:偽性低アルドステロン症II型. 日小児腎臓病会誌 27:71-75, 2014
 
6) Ellison DH:Pseudohypoaldosteronism Type II. In:Adam MP, et al.(eds), GeneReviews [Internet]. University of Washington, Seattle, Last Update:Feb 16, 2017 https://www.ncbi.nlm.nih.gov/books/NBK65707/
 

第12章 内分泌異常に関連するその他の疾患

P.281 掲載の参考文献
1) 高橋三郎, 他(監訳):食行動障害および摂食障害群. DSM-5 精神疾患の診断・統計マニュアル. 医学書院, 323-347, 2014
 
2) Bryant-Waugh R, et al.:Overview of eating disorders in childhood and adolescence. In:Lask B, et al.(eds), Eating Disorders in Childhood and Adolescence. 4th ed., Routledge, Hove;New York, 33-49, 2013
 
3) 日本小児心身医学会(編):小児科医のための摂食障害診療ガイドライン. 小児心身医学会ガイドライン集. 改訂第2版, 南江堂, 117-214, 2015
 
4) 厚生労働科学研究(子ども家庭総合研究事業)思春期やせ症と思春期の不健康やせの実態把握および対策に関する研究班(編著):思春期やせ症-小児診療に関わる人のためのガイドライン. 文光堂, 2008
 
5) Misra M, et al.:Endocrine consequences of anorexia nervosa. Lancet Diabetes Endocrinol 2:581-592, 2014
PubMed
P.286 掲載の参考文献
1) Children's Oncology Group:Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers. Version 5.0, 2018 http://www.survivorshipguidelines.org/
 
2) 日本小児内分泌学会(編):小児がん内分泌診療の手引き, 診断と治療社, 2021
 
3) Vatner RE, et al.:Endocrine Deficiency As a Function of Radiation Dose to the Hypothalamus and Pituitary in Pediatric and Young Adult Patients With Brain Tumors. J Clin Oncol 36:2854-2862, 2018
 
4) Arima H, et al.:Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors:clinical guidelines of the Japan Endocrine Society. Endocr J 66:581-586, 2019
PubMed
5) Maciel J, et al.:Growth hormone deficiency and other endocrinopathies after childhood brain tumors:results from a close follow-up in a cohort of 242 patients. J Endocrinol Invest 44:2367-2374, 2021
 
6) Brownstein CM, et al.:Factors that affect final height and change in height standard deviation scores in survivors of childhood cancer treated with growth hormone:a report from the childhood cancer survivor study. J Clin Endocrinol Metab 89:4422-4427, 2004
PubMed
7) 厚生労働科学研究費補助金難治性疾患等政策研究事業「間脳下垂体機能障害に関する調査研究」班(編):成人成長ホルモン分泌不全症の診断と治療の手引き(平成30年度改訂). 日内分泌会誌 95(Suppl.):36-39, 2019 https://www.jstage.jst.go.jp/article/endocrine/95/S.May/95_1/_pdf/-char/ja
 
8) Grimberg A, et al.:Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents:Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency.Horm Res Paediatr 86:361-397, 2016
PubMed
9) Sklar CA, et al.:Hypothalamic-Pituitary and Growth Disorders in Survivors of Childhood Cancer:An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 103:2761-2784, 2018
PubMed
10) 間部裕代:間脳-下垂体近傍腫瘍. 日本小児内分泌学会(編), 小児内分泌学. 改訂第3版, 診断と治療社, 239, 2022
 
11) Biondi B, et al.:Treatment with thyroid hormone. Endocr Rev 35:433-512, 2014
PubMed
12) Delvecchio M, et al.:Levothyroxine requirement in congenital hypothyroidism:a 12-year longitudinal study. Endocrine 50:674-680, 2015
PubMed
13) Shimon I, et al.:Thyrotropin suppression by thyroid hormone replacement is correlated with thyroxine level normalization in central hypothyroidism. Thyroid 12:823-827, 2002
PubMed
14) Inskip PD, et al.:Hyperthyroidism After Radiation Therapy for Childhood Cancer:A Report from the Childhood Cancer Survivor Study. Int J Radiat Oncol Biol Phys 104:415-424, 2019
 
15) Khanna A, et al.:Increased Risk of All Cardiovascular Disease Subtypes Among Childhood Cancer Survivors:Population-Based Matched Cohort Study. Circulation 140:1041-1043, 2019
PubMed
16) 日本高血圧学会高血圧治療ガイドライン作成委員会(編):高血圧治療ガイドライン2019, ライフサイエンス出版, 2019
 
17) Pradhan KR, et al.:Endocrine and Metabolic Disorders in Survivors of Childhood Cancers and Health-Related Quality of Life and Physical Activity. J Clin Endocrinol Metab 104:5183-5194, 2019
PubMed
P.289 掲載の参考文献
1) Halton J, et al.:Advanced vertebral fracture among newly diagnosed children with acute lymphoblastic leukemia:results of the Canadian Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) research program. J Bone Miner Res 24:1326-1334, 2009
PubMed
2) 骨粗鬆症の予防と治療ガイドライン作成委員会(編), 骨粗鬆症の予防と治療ガイドライン2015年度版, 2015 http://www.josteo.com/ja/guideline/doc/15_1.pdf
 
3) Bishop N, et al.:Fracture prediction and the definition of osteoporosis in children and adolescents:the ISCD 2013 Pediatric Official Positions. J Clin Densitom 17:275-280, 2014
PubMed
4) Suzuki Y, et al.:Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research:2014 update. J Bone Miner Metab 32:337-350, 2014
PubMed
5) Buckley L, et al.:2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol 69:1521-1537, 2017
PubMed

書評

最近チェックした商品履歴

Loading...